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Abstract
Patients in palliative care suffer from a life-threatening disease.
Holistic treatment includes control of symptoms (e. g., pain, nausea,
sleeplessness) as well as psychosocial and spiritual help which is also
extended to the relatives of a patient. For advanced cancer patients
in palliative care, a crucial phase is the transition from palliative care
in the hospital to the home setting, where care around the clock is
not guaranteed any more, leads to an increased number of unplanned
hospital re-admissions and emergency visits. Physicians aim to fill this
care gap by monitoring physical and social activities as well as vital
signs. Daily monitoring data, provided to caregivers, could enable
caregivers to timely intervene when symptoms of a patient deteriorate.
Besides patients in palliative care, also cancer survivors suffering
from cancer-related fatigue could benefit from activity monitoring. Up
to now, the remedies and effective treatments for cancer-related fatigue
are limited. Research still has to unveil the underlying mechanisms that
lead to a state of chronic exhaustedness. Measures that help healthy
people like regenerative sleep show no or little effect in fatigued pa-
tients. Besides psycho-stimulants that come with the risk of addiction,
cognitive behavioural therapy and moderate physical exercise have
been shown to be effective. However, research still has to investigate
timing, frequency and intensity of physical activity and researchers
need a better understanding how the fatigue evolves during the day
and in long-term.
This thesis investigates the possibilities and limitations of activity
monitoring using wearable devices such as smartphones and an arm-
worn devices that is capable of measuring vital signs such as heart
rate. Three studies involving cancer patients are conducted:
• An interview study including 12 cancer patients enabled a
patient-centric design for an Android activity monitoring app
for smartphones.
• Only using the smartphone as monitoring device, a study with 7
cancer survivors suffering from cancer-related fatigue was con-
ducted as a pre-study in order to gain first experiences and to
explore the possible knowledge gain about cancer-related fatigue
through activity monitoring.
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• During a planned study period of 12 weeks per patient, 30 pa-
tients in ambulatory palliative care were wearing a smartphone
and the arm-worn sensor as monitoring devices. The age range of
the study participants was 39 to 85 years. In weekly interviews,
patients were asked about their experiences with the devices and
their quality of life. The aim of the study was to evaluate feasibil-
ity and acceptance of activity monitoring in this patient group.
Furthermore, exploratory data analysis investigated the possibil-
ities and limitations of unsupervised methods on this real-world
data set.
The two data sets, collected during the fatigue study and during
the palliative care study, were pre-processed including cleaning steps,
classification and clustering methods to add higher level information
such as visited locations (anonymized). From these prepared data sets,
features were extracted such as number of places visited per day. On
the resulting datasets of features, statistical methods were applied to
explore relations between sensor data, self-reports and, in case of the
palliative care study, emergency visits to the hospital. For the latter
analysis, patients who experienced an emergency room visit and those
who did not were compared by means of hypothesis testing. For each
feature, the underlying alternative hypothesis was that the change of a
feature between the first week of study participation at home and the
week before an emergency visit (or the last week of study participation
for the patients without an emergency visit), differs in the two patient
groups. The rate of change was defined by the ratio of the medians of
the two weeks. Changes of three features, namely resting heart rate,
resting heart rate variability and step speed were identified to have
significant group differences:
• The resting heart rate had an increasing trend in the group with
emergency visits (median=1.01, interquartile range [0.96, 1.12])
and a decreasing trend in the group without an emergency visit
(median=0.9, interquartile range [0.89, 0.99]) with a nominal sig-
nificance of p=.021 and a medium effect size r=.46.
• The resting heart rate variability had a decreasing trend in
the group with emergency visits (mean=0.81, standard devia-
tion=0.14) and an increasing trend in the group without an emer-
gency visit(mean=1.17, standard deviation=0.46) with a nominal
significance of p=.011 and a large effect size r=.53.
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• The step speed had an increasing trend in the group with emer-
gency visits (median=1.1, interquartile range [1.08, 1.13]) and a
decreasing trend in the group without an emergency visit (me-
dian=0.99, interquartile range [0.96, 1.04]) with a nominal signif-
icance of p=.003 and a large effect size r=.61.
In contrast, hypothesis testing for features based on patients’ subjective
self-reports for pain, distres and global quality of life did not reveil
any significant differences. Hence, activity monitoring of vital signs
and physical activity outperformed patients’ self-reports. However, a
power analysis based on the three nominally significant results would
recommend an independent study with 84 patients to confirm the
results of this study.
Furthermore, a set of recommendations for future research was con-
cluded from the experiences gained through conducting these studies.

Zusammenfassung
Patienten in Palliativbetreuung leiden an einer lebensbedrohlichen
Krankheit. Die Behandlung folgt einem holistischem Ansatz, der
Symptommanagement (z.B. von Schmerzen, Übelkeit, Schlaflosigkeit
usw.) sowie psycho-soziale und spirituelle Hilfe, die auch die Ange-
hörigen des Patienten einschliesst, umfasst. Für Krebspatienten im
fortgeschrittenen Stadium ist die Übergangsphase nach der Entlas-
sung aus dem Spital nach Hause besonders kritisch, da im häus-
lichen Umfeld die rund-um-die Uhr Betreuung aus der Klinik nicht
mehr gewährleistet ist. Diese Umstellung führt zu vermehrten unge-
planten Wiederaufnahmen und ambulanten Besuchen im Notfall.
Ärzte möchten diese Versorgungslücke durch Überwachung von phy-
sischer und sozialer Aktivität sowie von Vitalparametern der Patienten
füllen: täglich bereitgestellte Monitoringdaten könnten es Betreuern er-
möglichen, zur richtigen Zeit einzugreifen, wenn sich die Symptome
eines Patienten verschlechtern.
Neben Patienten in Palliativpflege könnten auch Krebsüber-
lebende, die an sogenannter tumorassoziierter Müdigkeit (Fatigue)
leiden, von Aktivitätsmonitoring auf folgende Weise profitieren: bis
jetzt sind die Mittel und effektive Behandlungsmethoden gegen krebs-
assoziierte Müdigkeit eingeschränkt. Die Forschung muss noch die
zugrundeliegenden Mechanismen, die zu dieser Art von chronischer
Erschöpfung führen, erklären. Massnahmen wie beispielsweise erhol-
samer Schlaf, die gesunden Menschen gegen Müdigkeit helfen, zeigen
keinen oder nur geringen Effekt bei chronisch müden Patienten. Neben
Psychopharmaka, die abhängig machen können, wurde für kogni-
tive Verhaltenstherapie und modarates physisches Training Effekti-
vität gegen Fatigue durch Studien gezeigt. Jedoch muss die Forschung
noch eingehender untersuchen, wann, in welcher Häufigkeit und mit
welcher Intensität optimalerweise trainiert werden sollte. Dazu ist es
auch notwendig, besser zu verstehen, wie die Fatigue sich im Verlaufe
eines Tages und über einen längeren Zeitraum hinweg entwickelt.
Diese Arbeit untersucht die Möglichkeiten und Grenzen von Akti-
vitätsmonitoring mithilfe von tragbaren Geräten wie Smartphones und
ein am Oberarm getragener Sensor namens Everion R©. Drei Studien
wurden mit Krebspatienten durchgeführt:
• Eine Interviewstudie mit 12 Krebspatienten hat ein patienten-
gerechtes Design einer Aktivitätsmonitoring-App für Android
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Smartphones ermöglicht.
• In einer Vorstudie wurden 7 Krebsüberlebende, die an tumoras-
soziierter Fatigue leiden, nur mit einem Smartphone als Moni-
toringgerät ausgestattet. Diese Vorstudie diente dem Sammeln
erster Erfahrungen und der Erforschung, welcher Information-
sgewinn bzgl. tumorassoziierter Fatigue durch Aktivitätsmoni-
toring möglich ist.
• Während einer geplanten Studiendauer von 12 Wochen pro Pa-
tient trugen 30 Krebspatienten in ambulanter Palliativepflege
ein Smartphone und den Everion R© als Monitoringgeräte. In
wöchentlichen Interviews wurden sie bzgl. ihrer Erfahrungen
mit den Geräten und ihrer Lebensqualität befragt. Das Ziel der
Studie war es, die Machbarkeit und Akzeptanz von Aktivi-
tätsmonitoring in dieser Patientengruppe in einem Alter bis zu
85 Jahren zu erforschen. Ausserdem wurde eine explorative Da-
tenanalyse durchgeführt und die Möglichkeiten und Grenzen
von unüberwachten Methoden auf diesem Datensatz aus der
“wirklichen Welt” untersucht.
Die beiden Datensätze, die während der Fatigue-Studie und der
Palliativ-Studie erhoben wurden, wurden aufbereitet, was Datensäu-
berungsschritte, Klassifizierungen, Clusteringmethoden zum Anreich-
ern mit aus den Sensordaten gewonnener Informationen wie Anzahl
besuchter Orte pro Tag und die Extrahierung von Merkmalen beinhal-
tete. Auf die daraus gewonnenen Datensätze, bestehend aus den ex-
trahierten Merkmalen, wurden statistische Methoden angewandt, um
Zusammenhänge zwischen den Sensordaten, Selbsteinschätzungen zu
Symptomen und, im Falle der Palliativ-Studie, ambulante und sta-
tionäre Notfallbesuche, aufzuzeigen. Als Ergebnis konnten drei Merk-
male, nämlich der Ruhepuls, Herzratenvariabilität in Ruhe und die
vom Smartphone gemessene Schrittgeschwindigkeit identifiziert wer-
den. Diese drei Parameter zeigten signifikante Unterschiede zwischen
den beiden Patientengruppen:
• Der Ruhepuls zeigte einen steigenden Trend in der Gruppe
mit Notfallbesuchen (median=1.01, Interquartilsabstand [0.96,
1.12]) und einen fallenden Trend in der Gruppe ohne Notfallbe-
such (median=0.9, Interquartilsabstand [0.89, 0.99]) mit einer
nominellen Signifikanz von p=.021 und einer mittleren Effekt-
grösse r=.46.
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• Die Herzratenvariabilität in Ruhe zeigte einen fallenden Trend
in der Gruppe mit Notfallbesuchen (mean=0.81, Standardab-
weichung=0.14) und einen steigenden Trend in der Gruppe
ohne Notfallbesuche (mean=1.17, Standardabweichung=0.46)
mit einer nominellen Signifikanz von p=.011 und einer grossen
Effektgrösse von r=.53.
• Die Schrittgeschwindigkeit zeigte einen leicht steigenden Trend
in der Gruppe mit Notfallbesuchen (median=1.1, Interquartilsab-
stand [1.08, 1.13]) und einen leicht fallenden Trend in der Gruppe
ohne Notfallbesuche (median=0.99, Interquartilsabstand [0.96,
1.04]) mit einer nominellen Signifikanz von p=.003 und einer
grossen Effektgrösse r=.61.
Im Gegensatz dazu, Hypothesentests für Merkmale basierend auf den
Selbstberichten von Patienten für Schmerz, Belastung und globaler
Gesundheitsstatus haben keine signifikanten Unterschiede zwischen
den beiden Gruppen aufgedeckt. Eine Poweranalyse basierend auf den
drei nominell signifikanten Ergebnissen empfiehlt eine unabhängige
Studie mit 84 Patienten, um die Ergebnisse dieser Studie zu bestätigen.
Empfehlungen für zukünftige Forschung wurden aus den Er-
fahrungen, die in den während dieser Arbeit durchgeführten Studien
gewonnen wurden, gesschlossen.

1
Introduction
The introduction motivates observational studies to examine the feasibility
and usefulness of monitoring severely ill patients by means of wearables.
2 Chapter 1: Introduction
1.1 Background, Motivation and Aim
1.1.1 Palliative Care
Background. The World Health Organisation’s (WHO) 2014 cancer
report estimated in 2012 that 8.7 million people over 15 years old had
been diagnosed with a cancer disease the year before, 22 million in the
previous three years and more than 32 million people in the previous
five. Furthermore, the WHO estimates that over 19 million adults are
in need of palliative care (PC) at the end of life with 34 % having
cancer [1]. Other life-threatening diseases are cardiovascular diseases
and chronic obstructive pulmonary disease.
Unlike curative care, palliative care does not aim to cure a disease,
but instead to provide the best possible quality of life by following a
holistic approach: control of symptoms (e.g., pain, nausea, sleepless-
ness) as well as psychosocial and spiritual help which is also extended
to the relatives of a patient [2].
Motivation. Whereas hospitals, hospices and nursing homes provide
PC around the clock, patients usually don’t have this 24/7 professional
support in the home environment. The transition from hospital to home
is an especially crucial phase for patients and their relatives, leading
to a relevant number of unplanned re-hospitalisations and emergency
visits [3]. Patients possibly have to adjust to symptoms (e.g. pain) or a
changed body schema (e. g., loss of weight) resulting from the progress
of the disease or stressful therapy. In addition, they have to face an
extended comprehension (understanding) of their disease. At the same
time, with the discharge from hospital they lose the support of an
interdisciplinary professional team that has been available around the
clock. Re-hospitalisation through emergency visits happens also due
to suffering from symptoms that could have been effectively treated
in the ambulatory setting – if detected in time. Delgado-Guay et al.
give changes in the mental status, dyspnea, fever, infections, etc. as
main reasons for admittance to the emergency department. They rated
23 % of emergency visits by patients with advanced cancer receiving
palliative care as potentially avoidable with constipation and running
out of pain medications as main causes [4].
Basch et al. showed that symptom monitoring during chemother-
apy treatment by the means of electronic patient-reported outcomes
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improve health-related quality of life, reduces emergency visits and
hospitalisations and prolongs survival [5, 6].
However, Pakhomov et al. found disagreement between patient-
reported symptoms and their documentation in medical records [7].
Hence, this thesis examined if more reliable symptom-related infor-
mation can be collected through continuous monitoring of physical
activity and of vital signs. The feasibility and information gain are
examined in this work and results are presented in Chapter 5.
1.1.2 Cancer related fatigue
Background. Cancer survivors have to deal with the side effects of
the disease even after having defeated it. One of the most prevalent
problems is cancer related fatigue (CRF): almost all cancer patients
suffer from CRF during treatment [8] and about 25 % of cancer sur-
vivors have to deal with CRF after successful treatment for up to 10
years [9]: the exhausting treatment and stressful situation of the severe
disease are finished, yet CRF patients still feel constantly exhausted on
a physical and psychological level. Furthermore, usual behaviours like
regenerative sleeping do not improve the tiredness of CRF patients.
The etiology of CRF is complex and includes physiological causes
related to cancer treatment and medication as well as behavioural fac-
tors such as fear, depression or insomnia and reduced physical activity
[9].
A moderate to severe CRF reduces physical and mental capabili-
ties. This can lead to an inability to work, impairment of social life,
daily activities and hobbies, and can also negatively impact relation-
ships. Overall, this huge negative interference with daily life reduces
quality of life [10, 11]. During FATIGUE2 study [10], 376 patients were
interviewed about the physical, emotional, behavioural and econom-
ical impact of fatigue after being treated with chemotherapy. 90 % of
the interviewed patients suffered from fatigue (n = 301) and reported
that CRF prevents them from leading a normal life. Curt concludes
that CRF reduces quality of life (QoL) more than other symptoms [10].
Motivation. Psychological interventions and psycho-stimulant drugs
have been used as therapies although evidence of efficacy is still low
for both categories of intervention. both categories of intervention,
evidence is still low. Drugs have negative side effects and a risk of
addiction, leading to increased research for alternatives. Studies have
4 Chapter 1: Introduction
shown evidence for cognitive behavioural therapy, mindfulness-based
meditation [12], physical interventions including moderate physical
exercise, walking or yoga [13]. However, more research is required to
reveal deeper knowledge and understanding of the underlying mech-
anisms of the disease. More detailed and individualised recommen-
dations are needed on when, how often, how much and what type of
exercise is most effective in the context of other diseases as well, such
as depression [14].
After a systematic review of studies investigating CRF, Prue et al.
concluded that studies should have a longitudinal design including
frequent assessments of the fatigue and a healthy control group [15].
Kelley et al. confirm Prue with their conclusion that “additional well-
designed randomised controlled trials and meta-analyses appear war-
ranted” [16].
This work examines how activity monitoring and digital question-
naires provided by the smartphone (that is used by patients anyway)
could be applied in longitudinal studies, realising a fatigue assessment
with a frequency of several times per day. The study goal is to gain
information concerning the course of fatigue, patients’ behaviour and
physical activity. Results are presented in chapter 4.
1.2 Goals of this work
From the motivation of section 1.1, the following questions are derived:
• How should a monitoring system look like in order to reduce
non-elective re-admissions to hospital for outpatients in pallia-
tive care?
• Is activity monitoring accepted by patients that have to deal with
a severe disease and face their end of life?
• Which sensor modalities are useful in order to predict non-
elective re-admissions to hospital?
In order to answer these research questions, this work investigated
the usage of two wearable devices that are mobile and can be worn on
the body (not hand-held) in the setting of ambulatory palliative care.
Cancer related fatigue. As part of a pre-study with reduced setup
and shorter study period, 8 patients suffering from CRF received a
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smartphone with a pre-installed activity monitoring app. Beside col-
lecting data from various phone sensors as described in chapter 2,
patients had to fill out digital questionnaires several times per day.
Study aims were to
• evaluate the acceptance of activity tracking with smartphones in
this patient group
• test the developed monitoring system as described in chapter 2
and test the design of digital questionnaires
• evaluate the information gained from the collected data
Palliative Care. During an observational study including 31 patients
(one patient passed away few days after discharge to home) in ambu-
latory palliative care, the study participants received an arm-mounted
sensor and a smartphone with a pre-installed activity monitoring app.
The study participants had to fill out digital questionnaires once a day.
Study aims were to
• evaluate the feasibility of remotely monitoring palliative pa-
tients’ vital signs, physical and social activity using the arm-
mounted sensor and a smartphone
• evaluate the developed monitoring system as described in chap-
ter 2
• analyse behavioural pattern in patients with deteriorating symp-
toms
1.3 Wearable technology for measuring vital signs and
physical activity
Wearable devices are devices that can be worn on the body without the
using hands to carry them. They come in the form of accessories like
bracelets, anklets, armbands, contact lenses, necklaces, glasses, rings
and watches, but also as part of clothes, e. g., shirts, shoes and jackets
[17] and the smartphone worn in a pocket or on a belt.
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1.3.1 Photoplethysmography
Photoplethysmography (optical method to measure heart rate) (PPG) is
used to measure pulse-related parameters such as heart rate. [18] gives
an overview over the measurement principle, the current technology
and clinical applications. The technique is implemented in devices
such as pulse oximeters and smartwatches. The measurement princi-
ple is based on light transmission or reflection: measurement devices
are equipped with LEDs that send light of different wavelengths into
the human body. The blood flow influences the transmitted or reflected
light which is received by a photodiode. From this measurement, sev-
eral vital signs such as heart rate (HR), respiration rate (RR), energy
expenditure (EE), peripheral capillary oxygen saturation (SpO2), etc.
can be derived. Measurement quality is limited by tattoos at the mea-
surement spot and artifacts introduced by movement. Other crucial
factors that influence the measurement quality are contact to skin and
blood perfusion. The performance of wrist-worn sensors is better dur-
ing resting and worsens with increasing impact with a deviation in
heart rate measurement below 10 % [19]. Georgiou et al. stated that
wearable PPG-based measurements of heart rate variability (HRV) can
be an alternative to standard techniques for resting or mild exercise
conditions.
1.3.2 Accelerometer
Smartphones are equipped with a tri-axis accelerometer which is used
for many smartphone functions such as turning on the screen when
grabbing the phone as well as for activity recognition, e. g., counting
steps.
1.3.3 GPS
Smartphones normally are equipped with a GPS module for locali-
sation purposes. The currently used sensors are basic modules with
lower accuracy than more advanced modules. Smartphones use also
the information of Wi-Fi (Wi-Fi) signals and provider network infor-
mation to improve localisation accuracy leading to errors up to 6 % for
distance measuring [20]. When outdoors in nature, the deviance is on
average 10 m [21]. However, the accuracy of Global Positioning System
(GPS) measurement in cities or while being indoors decreases due to
the surroundings that block the direct sight to GPS satellites [22].
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1.3.4 Wi-Fi
Wi-Fi is the commonly used name for the IEEE 802.11 standard for
wireless networking. An access point (AP) is a device providing a Wi-
Fi network. Client devices like smartphones are scanning regularly for
APs. Smartphones use the scan results to improve GPS based locali-
sation. Furthermore, it is possible to record the receive signal strength
indicator (RSSI). The RSSI depends on the signal propagation. Different
material such as metal, brick walls, etc., attenuate differently the signal
sent by APs which leads to characteristics of, e. g., rooms, so-called
fingerprints. Wi-Fi fingerprinting is a common technique for indoor-
localisation. The smartphones used in this work detected signals with
a minimum RSSI of −103 dBm.
1.4 State of the art
State of the art used throughout this thesis comprises several fields.
The first section focuses on solutions for remote monitoring as well as
the application of information and communication technology (ICT)
for disease and symptoms management in several medical fields. The
second section gives an overview over the usage of wearables for health
care and well-being. The following sections focus on the extraction
of higher-level information out of raw sensor signals, where more
complex methods are needed. The last section gives an overview over
currently available methods for prediction.
1.4.1 Remote monitoring and ICT for disease management
Cardiovascular diseases
Especially with the treatment by means of implantable devices, e. g.,
pacemaker and implantable cardioverter defibrillators (ICDs), remote
monitoring is already well established in the field of cardiovascular
diseases. Pacemakers and ICDs collect vital sign measurements, infor-
mation about occurred heart rhythm anomalies and the device status
during their regular functioning. On a daily basis, they send the col-
lected data to manufacturers who provide summaries to health carers.
These summaries include among others early indicators for a deteri-
oration of the disease, e. g., worsening of the heart function. Device
manufacturers routinely perform clinical trials to show the efficacy of
new devices and device functionalities, including monitoring services.
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[23, 24, 25, 26] showed reduced all-cause mortality and hospitalisation
for heart failure patients with remote monitoring.
In addition to implant based-solutions, research has also inves-
tigated feasibility and efficacy of non-invasive monitoring systems.
Common approaches are based on structured telephone support, reg-
ular manual self-assessments transmitted via ICT or measurement de-
vices. These devices measure body signs such as weight, blood pres-
sure, heart rate and heart rhythm. The collected data is automatically
transmitted to a telemonitoring centre either by means of a built-in
modem or through a mobile phone that is connected via Bluetooth
[27, 28]. Bashi et al. give an overview of systematic reviews. Typical
study outcomes are, e. g., mortality (all-cause and specific), hospital-
isation and quality of life. In general, studies agree on the positive
impact of monitoring and show significant outcomes improvement.
Bashi et al. conclude that physiological monitoring should be part of
the daily care for HF patients [29].
Mental and neurological diseases
Giunti et al. give an overview over commercially available smartphone
applications for multiple sclerosis (Multiple Sclerosis (MS)) patients
[30]. They state that although MS is one of the dominant neurological
diseases, the available apps are underrepresented in comparison to
diseases like cancer, diabetes or HIV.
Mental diseases
For depression, various studies have evaluated the efficacy of interven-
tions, e. g., based on cognitive behavioural therapy and mindfulness
meditation [31, 32]. Firth et al. conclude that smartphones are promis-
ing tools for managing depression and supporting interventions like
cognitive behavioural therapy (cognitive behavioural therapy (CBT)).
Palliative care and oncology
Although remote monitoring is already established and has been
proven to be effective in reducing re-hospitalisations and mortality
in several fields as described above in sections 1.4.1, 1.4.1, 1.4.1, there
are not any established solutions for palliative care patients. Various
research on ICT systems has already shown some evidence on usage of
web-based and mobile phone applications, e. g., to support symptoms
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management, to improve contact between patients and care givers
over distance [33, 34] or intervention (e.g., nutrition, social network,
physical exercises) apps to improve quality of life [35]. Kawsar et al.
investigate feasibility and challenges for the digitalisation of the paper-
based questionnaires ESAS for breast cancer patients in Bangladesh.
They focus on research with rural populations in developing coun-
tries. They concluded that the digital questionnaire on a smartphone
has advantages (e. g., reducing long, exhausting commuting to physi-
cians) and plan to extend their research on automatic physical tracking
using smartphones [36].
[37] reviews actual research concerning web-based tools for self-
management in patients with cancer related fatigue. Studies evaluating
interventions for fatigued cancer survivors showed small to moderate
effects to improve quality of life and depression [38]. The usage of
mobile technology for collection of patient subjective reported outcome
is already established in oncology [39, 40, 41].
Andebe et al. studied the usefulness of a mobile phone assessment
in 15 palliative patients and caregivers in an African population by
performing qualitative interviews after an usage period of 6 weeks
[34]. Andebe et al. concluded that the mobile phone assessment tool
improved communication between patients and caregivers as well as
symptoms management. However, the authors did not list detailed
inclusion criteria concerning patient characteristics and none of the
work included in this literature research involves wearable sensing
technologies.
1.4.2 Wearables for well-being, healthy behaviour and disease mon-
itoring and management
Wearable technology
Smartphone apps for a healthier lifestyle and wrist-worn fitness track-
ers as well as smartwatches are already a commercial hype with over
100 million fitness tracker devices sold in 2016 [42]. However, the mea-
surement accuracy of these devices is shown to be low, underestimating
the heart rate (HR) up to 30 bpm (beats per minute), especially during
exercising [42, 19]. An overview of the wrist-worn fitness trackers that
were available for consumers in 2017, evaluates the monitoring of heart
rate, energy expenditure (EE) and physical activity (step count). Bunn
et al. confirm the tendency to underestimate the measured variables
[43]. The authors summarise, that in general, the devices underes-
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timates the heart rate and the energy expenditure, although perform
better during sedentary activities and worse during exercising. In addi-
tion, the errors augment when the arm wearing the device increases its
movement. The reason behind this observation lies in the measurement
method: increased movement alters the blood flow inducing artifacts
that hinder accurate measurements. In contrast, the devices perform
better in step counting with increased speeds (3.22 km/h to 8.05 km/h)
and underestimate the step count with speeds < 3.22 km/h. The re-
searchers give as possible reasons instability and wrong positioning at
the wrist. Gillinov et al. evaluated the accuracy of a chest strap, one
monitor worn at the fore-arm and four wrist-worn heart rate monitors
from different brands against a standard ECG measurement in healthy
subjects while exercising. They conclude that electrode-based moni-
tors (e. g., chest strap) outperform optical sensors and the accuracy of
optical sensors depend on the type of activity a user is doing [44].
[45, 46, 47, 48] present reviews on monitoring systems for health
care, activity recognition and stress detection. The accuracy and granu-
larity in the activity recognition depend on the number and placement
of sensors, which in return affects the system obtrusiveness to users
[49].
However, when being used for research, wearables have to fulfil
specific requirements, e. g., full access on collected raw signals and full
control over data accessibility – depending on national laws concerning
data security, privacy and clinical trials that have to been approved
by a national or local ethical committee. A market research revealed
only three available unobtrusive devices: Empatica E4 1, the Angel
Sensor that was developed by a startup and whose development was
shut down by the end of 20162 and the Biovotion Everion R© that is CE
certified as a medical device in compliance with directive EC 765/2008
and also benefits from FDA approval (Food and Drug Administration3)
as a class 2 device.
1https://store.empatica.com/products/e4-wristband?variant=39588207747
2http://www.mobihealthnews.com/content/open-source-wearable-angel-shuts-down
3federal agency of the United States Department of Health and Human Services that
is responsible to approve food, medication, medical devices etc. for the U.S. market
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Relationship between wearable monitoring and symptoms and dis-
eases
In various studies, activities were shown to be related to pain level [50]
and mental health [51].
The group of Tanzeem Choudhury investigated the usage of the
smartphone itself to assess the user’s well-being. [52, 53, 54] propose
systems that range from monitoring and visualising the user’s be-
haviour in terms of physical and social activity as well as sleep hy-
giene to systems providing interventions like timely suggestions of
alternative healthy behaviours for the app user.
Research on the management of mental diseases with the support
of wearables focuses on schizophrenia [55, 56, 57], depression [58],
bipolar disorder [59, 60, 61] and stress [62, 63]. Also the usage of wear-
ables in the field of neurological diseases such as Multiple Sclerosis
[64, 65] and Parkinson [66] is investigated. Smartphone-based symp-
tom assessment for Parkinson was evaluated in [67] showing high
correlations with several standardised disease scales (r = .72 up to
r = .91, all <= 0.002).
Timmerman et al. examined the relationship between cancer re-
lated fatigue and daily physical activity using acceleration sensors. The
study showed no significant difference between the fatigued group and
a control group, but a significant decrease in the activity from morning
to evening as well as a positive correlation between the self-reported
fatigue level and the magnitude of the decrease from afternoon to
evening. Timmerman et al. concluded that monitoring reveals pat-
terns of fatigue and physical activity and therefore could be used to
improve the treatment of fatigue [68].
1.4.3 Heart rate variability analysis
Medical significance of heart rate variability
HRV was extensively examined since 1965 [69] leading to standardised
nomenclature and measurement methods in 1996 [70]. Researchers
have shown that the HRV provides information about the state of
the autonomic nervous system [71], blood pressure, renal function
failure, diabetes and other diseases [72]. [73] gives an overview on
HRV in epilepsy and confirms the significance of several HRV features
for epilepsy. Frequency analysis focusing on low frequency band (LF)
and high frequency band (HF) frequency bands were shown to relate
12 Chapter 1: Introduction
with stress. Lower vagal and higher sympathetic tone estimated by
LF/HF ratio have been shown to predict morbidity and mortality in
cardiovascular diseases [74]. A relation between HRV features in the
frequency domain and (experimentally induced) pain was shown in
healthy subjects [72]. However, recent research also shows that HRV
needs to be studied more [75, 76], e. g., including high mental stress
and low physical stress situations, in order to develop HRV metrics
that discriminate better between mental and physical stress and are
related with sympathetic and vagal activities.
Significance of HRV in cancer patients
Studies examining HRV in cancer patients and advanced cancer pa-
tients concluded that HRV predicts overall survival [77, 78]. [79] ex-
amines the HRV response to opioid treatment against breakthrough
pain and identifies a frequency domain HRV feature as potential indi-
cator for pain. Study results in predicting the admission outcome are
contradictory and often based on small sample sizes [80]. However,
the behaviour of HRV in advanced cancer patients is still relatively
unknown. In contrast to a healthy population, there does not exist any
normal ranges of HRV metrics for cancer patients.
Methods for HRV analysis
Besides research on the application and clinical meaning of HRV, au-
thors also developed methods for HRV analysis, e. g., signal prepro-
cessing and effects of bad data quality. The effects of missing data on
time and frequency domain HRV analysis were studied in depth by
K. Kim et al.[81, 82]. Several authors also proposed methods to detect
and correct ectopic beats as an essential part of the signal preprocessing
[83]. However, the studies do not consider a continuous measurement
of HRV in an ambulatory setting.
1.4.4 Clustering of GPS data
The GPS signal of smartphones is used by various applications such
as navigation apps and provides useful information in various studies
such as examining recreational movement [21]. The studies described
in this thesis investigate behavioural patterns such as leaving home,
daily covered distance or number of visited places. Therefore, a set of
GPS points has to be partitioned into groups that represent meaningful
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places, so-called points of interest (Point of interest (POI)). Not every
location is also a place, e. g., if you are stuck in traffic at a highly
frequented crossing close to a beer garden for an hour, this sample of
20 GPS points (in case of requesting a GPS sample every 3 min) builds
a cluster, but not a meaningful place in the context of the studies of
this thesis, whereas if you go for a beer and actually sit in the beer
garden for an hour, the sample of 20 GPS points that is just a hundreds
of meters away from the traffic jam cluster, could be a meaningful
place. Data collected during the studies of this work does not contain
any ground truth concerning patient location. Hence, the following
paragraph summarises the state of the art of unsupervised methods.
Extracting places from GPS data in an unsupervised setting is based
on clustering the recorded set of GPS points. In case of spatio-temporal
data, a data sample contains also a timestamp, in addition to the loca-
tion information. A special case of spatio-temporal data are trajectories
that are recorded by moving instances. [84, 85] give overviews on the
commonly used approaches for clustering spatio-temporal data. Con-
cerning trajectories, there are two questions of interest. Firstly, for a
given trajectory, extract semantic information such as stops and moves
(intra-trajectory clustering). Secondly, for a given set of trajectories,
identify groups of similar trajectories (inter-trajectory clustering) [86].
In general, clustering approaches comprise distance-based meth-
ods, e. g., k-means (k-means), and density-based clustering methods
among others. The most commonly used density-based method is DB-
SCAN (Density-Based Spatial Clustering of Applications with Noise)
[87]. The advantage of DBSCAN over k-means is that one does not need
to specify the number of clusters. However, temporal-spatial datasets
usually do not have a uniform density. The algorithm OPTICS (Order-
ing Points To Identify the Clustering Structure) addresses this specific
characteristic of varying densities by finding clusters with varying
density [88]. Birant et al. extended DBSCAN to st-DBSCAN (spatio-
temporal DBSCAN) by adding a new arbitrary dimension, e. g., the
day and night average temperature measured at a location. Similar
points then have to be close enough in both dimensions [89]. Finally,
they also request that points are “temporal neighbours”, i. e., the sam-
ples are measured in “consecutive time units” [89]. For example, two
samples with the same location and with same 2nd dimension mea-
sured at, e. g., at 9 o’clock in the morning on two different days would
be part of two different clusters if the threshold for the time difference
is a day. However, this is not useful for the application in this thesis,
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where, e. g., the patient’s home should be one place independent of the
time.
Trajectories pose the additional challenge of connecting different
stays (a place where a person is staying for some amount of time).
Proposed methods to extract places out of trajectories are, e. g., SMoT
(Stops and Moves of Trajectories) [90], CB-SMoT (a clustering-based
algorithm to identify stops and moves of trajectories) [91] and DB-
SMoT (Direction-Based Stops and Moves of Trajectories) [92]. How-
ever, SMoT is based on providing additional information such as maps
and public POI. Therefore it is not suitable for applications with high
privacy concerns. CB-SMoT does not consider the possibility of revisit-
ing the same places: the home in the morning is classified as a different
stop than (the same) home in the evening.
1.4.5 Wi-Fi clustering
A map containing RSSI fingerprints is the basis for the commonly
used method to localise a device based on the RSSIs of detected APs.
Without this information, unsupervised clustering is still possible in
order to detect localisation changes at room level. However, aside from
walls, fluids, and hence the human body can influence Wi-Fi signals.
Therefore, the quality of a localisation method lies in its robustness
against such influences.
Research focuses on indoor-localisation with a known Wi-Fi envi-
ronment. The two most common approaches are based on tri-lateration
of RSSI values or on fingerprinting techniques. The first approach uses
the signal strengths of APs measured by the device that shall be located.
Using tri-lateration, the position can be estimated. This method is de-
ployable in public buildings, where the infrastructure is well known.
However, the method’s sensitivity to noise can introduce errors of
more than 20 m [93]. The second approach is based on creating Wi-Fi
maps, i. e., a database containing RSSI fingerprints. The position of a
device is then estimated by comparing the current fingerprint with the
database. This approach needs an initial effort of creating the map and
also demands maintenance in terms of updating the map since even
small environmental changes, e. g., adding fire doors to segment large
corridors, alternate Wi-Fi characteristics significantly [93]. Additional
limitations in accuracy are due to the physics of signal propagation, i. e.,
the human body can decrease the signal strength by around 10 dBm
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[94]. The variety of the built-in Wi-Fi receivers further induce inaccu-
racies [95].
Once there is a reliable map available, Kang et al. suggest to treat
a dataset of locations as a trajectory by involving also the time com-
ponent in order to improve the extraction of places. They suggest
an algorithm consisting of two steps: first, they use a mere distance
threshold between points that are adjacent in time in order to decide
if they belong to the same cluster or not. A cluster is considered as a
place if its size in terms of time exceeds a specified threshold. Before
adding a cluster to the list of places, their algorithm checks – again
by comparing its distance to existing places with a threshold – if the
cluster is added as a new place or merged with an existing place [96].
However, there is only little research for unsupervised scenarios.
Lau et al. propose DCCLA (Density-based Clustering Combined Lo-
calisation Algorithm) to cluster Wi-Fi scans from smartphones for a
room-level localisation [97]. The approach is split in two phases. Ini-
tially, DCCLA generates a database of fingerprints for rooms by com-
bining clusters of the same time frame using DBSCAN. They consider
a place as meaningful if a person stays for longer than 10 min. Af-
ter this learning period, DCCLA identifies the places based on the
stored fingerprints when a person is re-visiting. Xu et al. investigate in
depth DCCLA and state that the performance increases with a higher
amount of access points to up to 100 % accuracy [98]. However, during
their experiment, the smartphones were always placed on a table and
therefore with a fixed position in the room. Furthermore, they do not
provide an unsupervised solution for detecting new rooms: after the
initial creation of the fingerprint database, the algorithm needs user
input for rooms that are not yet in the database. Nevertheless, their
method could be extended by novelty detection or by using a distance
threshold up to which a point is considered to be sufficiently close to
a fingerprint.
1.4.6 Voice analysis
In this work, voice is analysed using voice features, not the content
of conversations. Research on this topic focused so far on artificially
produced datasets, e. g., EMO-DB [99] with German speech and RML
[100, 101] with multiple languages. The wizard-of-oz dataset is closest
to natural emotions because the study participants did not know that
they were recorded [102]. A review over emotional speech databases is
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given in [103] and over approaches is given in [104]. Usually, artificial
databases are created by recording actors saying defined utterances
playing different emotions. The quality of the recordings is verified
by having an audience rate the emotions. Recordings with insufficient
consistency are discarded. Typical emotions are, e. g.of EMO-DB, neu-
tral, anger, fear, joy, sadness, disgust and boredom. These emotions
can be ordered in two dimensions, namely arousal and valence. Some
approaches aim to classify only according to this two-dimensional
scheme.
Emotion analysis can be done online, e. g., EmoVoice [105, 106],
or offline, e. g., [107]. Both approaches are evaluated on artificial
databases. However, Vogt et al., the creators of EmoVoice, evaluated
commonly used feature sets for “acted and spontaneous speech”. They
concluded that features differ for acted and natural emotions. For the
first setting, pitch and pauses are dominating, whereas in the latter one,
Mel Frequency Cepstral Coefficients (MFCC) and their derivates are
more important [108]. Offline recognition performs better than online
recognition [105]. Binary classifiers for arousal and valence achieve ac-
curacies of up to 85 % [104]. The recognition of seven different emotions
achieves similar accuracies [109].
For applications like recorded phone calls, the recorded audio has
to be segmented in order to eliminate phases of silence and for speaker
diarization. Giannakopoulos provides a complete chain from feature
extraction, segmentation and classification [107].
There are also apps available that claim to detect emotions from
voice, e. g., GOOD VIBRATIONS sell an application programming in-
terface (API) and a software development kit (SDK) for emotion recog-
nition from audio, but they don’t provide any validation results to
show the performance of their classifier 4.
1.4.7 Overview over predictive modelling methods
Feature Selection
Commonly, feature selection increases model performance. Currently
used methods comprise wrappers that select a subset of features based
on the prediction performance an algorithm achieves with it. Prediction
performance usually is evaluated with cross-validation. Research was
done on search strategies since an exhaustive search is not feasible for
4http://www.good-vibrations.nl
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large sets of features. Greedy search strategies are efficient and have
the additional advantage to not overfit and can be designed as forward
selection and backward selection. Wrappers can be combined directly
with the training procedure, leading to embedded methods [110]. In
contrast to wrappers, filters do not involve a predicting model, but they
use metrics with less computational effort, e. g., mutual information or
based on correlation [110].
Classification
Common techniques for classification comprise, amongst others, Sup-
port Vector Machines (SVMs) and Random Forests (RFs)). They are
popular because they do not make any assumptions about the distri-
bution of features and normally find the important ones by themselves.
In addition, they are able to find non-linear decision boundaries. They
are used in a broad range of fields, e. g., activity recognition [111],
the above mentioned emotion extraction from voice and provide even
support for medical decisions [112].
Novelty and outlier detection
Novelty and outlier detection is of interest in a broad range of fields,
e. g., from supervision of manufacturing [113] to fraud detection[114],
e. g., for credit cards [115]. Common approaches estimate an anomaly
score for each data point. The anomaly score measures the degree of
being an outlier. This estimation can be based on principal compo-
nent analysis (PCA), the angle of vectors in the feature space (angle
based outlier detection (LOF)) or density based, i. e., considering the
reachability distance of points (local outlier factor (LOF)) [113].
Model-based approaches adapt classification methods to detect
novelty, e. g., the one-class-SVM of Schölkopf et al. and the IF [116].
Both methods can be trained with datasets containing no outliers. An
overview over one-class classifiers is given in [117].
If the underlying data are time series, breakout or change-point
analysis can be performed. Gurarie et al. developed a method to detect
behavioural changes based on change points in one-dimensional au-
tocorrelated Gaussian time series with missing data [118]. Anomalies
in data provide an additional challenge for change point analysis. One
can detect them first [119] and remove them or replace them using
an imputation method [120]. James et al. provide a breakout detection
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that is robust against anomalies and can be applied on the time series
directly [121]. Their approach is based on E-Divisive with Medians
(EDM) and works also for multivariate series [122].
Linear Mixed Models
For longitudinal studies that repeat measurements in individuals, lin-
ear mixed models are well-established. They have the advantage that
they deal well with missing or irregularly sampled data and take dif-
ferences in individuals into account by estimating fixed and random
effects [123].
1.5 Contributions
Aiming for the goals of section 1.2, this thesis makes the following
contributions:
Patient studies: Methods how to conduct studies with severely-ill pa-
tients involving wearables.
Monitoring system for severely-ill patients: A monitoring system
for physical and social activity tracking including monitoring of
vital signs that is developed following a patient-centric design.
Feature extraction pipeline: A data processing pipeline consisting of
necessary steps for preprocessing and data cleaning as well as
of methods based on machine learning to add higher level infor-
mation and to extract features for several sensor modalities. The
last two steps provide information about patients’ behaviour.
Datasets of CRF and PC patients: Comprehensive datasets contain-
ing activity data of CRF patients and activity and vital data of
palliative patients plus daily self-reports and weekly answers
to validated questionnaires. Evaluation of feasibility and accep-
tance of monitoring these patient groups.
Methods for analysis of the the datasets: Methods how to generate
knowledge out of the collected datasets.
Insights to the daily life of CRF and palliative patients: Discovery, vi-
sualisation and statistical analysis of behavioural changes, sub-
jective feelings of patients and features related to unplanned
re-admissions.
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1.6 Thesis outline
Chapter 2:
Monitoring System
Chapter 3:
Feature Extraction
Chapter 4:
CRF
Chapter 5:
PC
Figure 1.1: Thesis structure overview.
This thesis is structured as depicted in Figure 1.1. First, the methods
that are used in both studies are described, then the studies with their
outcome are presented.
Chapter 2 presents the monitoring system that was designed and
implemented with the focus of being deployed in the palliative care
and cancer related fatigue studies.
Chapter 3 describes the feature extraction for all collected sensor
data. It includes basic re-sampling as well as machine learning methods
such as clustering and supervised learning which is needed to either
enrich the dataset with additional information or to clean the dataset
from noise or invalid data.
Chapter 4 and 5 present the performed studies with cancer sur-
vivors suffering from cancer related fatigue and palliative patients in
ambulatory care. Each chapter comprises a description of the study
protocol, how the study was conducted, methods for study specific
data analysis as well as the study outcomes and results. Each chapter
closes with a study specific discussion including conclusions from the
results, limitations, recommendations and outlook for future research
on these fields.
Finally, chapter 6 summarises the thesis with overall limitations
and conclusions and gives an outlook on future work in the field of
using wearables in studies with severely-ill patients.
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2
The activity
monitoring system
and the conducted
studies
The chapter describes an activity monitoring system that was deployed in ob-
servational studies. Patient devices which were developed following a patient-
centric design, are described in detail. Finally, an overview on the conducted
studies is given.
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2.1 System overview
As described in section 1.1, this research is motivated by the idea of
a remote monitoring of palliative outpatients in order to reduce non-
elective re-admissions to hospital and emergency visits in the crucial
phase of transition from hospital to home. Figure 2.1 shows a moni-
toring system that could support patients in this transition phase. This
work focuses on the patient interface and data processing. In future,
a web-based interface could automatically provide information about
patients’ health status to care givers, e. g., to physicians. The moni-
toring system as shown in 2.1, was designed to be deployed in two
observational studies (ref. section 2.3 and section 2.4): for these stud-
ies, commercially available wearable devices have been integrated by
means of an Android app. Since the observational studies involve
digital questionnaires to be filled out by patients on a regular basis,
the designed app provides a user interface that has been developed
following a patient-centric approach.
questionnaires
continuous
wearing
continuous wearing
BLE transmission
Wi-Fi 
transmission
web-based
patient 
information
Patient
Doctor
realized
Figure 2.1: Overview over monitoring system: the Everion R© has been
deployed only in the palliative care study, the apps used in both studies
differ only in the user interface (digital questionnaires for patients and
configuration menu for staff). BLE: Bluetooth low energy
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2.1.1 System components
The activity monitoring system consists of two wearable devices,
namely a smartphone (typically a Samsung Galaxy S5) and an arm-
worn sensor (Everion R©) which provide the interface to the patients,
and of a data receiving server at ETH Zürich in Switzerland. Similar
systems were used in both studies. The differences have been marked
in the text.
2.1.2 Secure and reliable data transmission
The smartphone app sends encrypted data to a secured server at ETH
using the Wi-Fi infrastructure available at patients’ homes. If needed,
patients are provided with a mobile hotspot. By using a Wi-Fi network,
patients are not charged by their carrier for mobile data usage. Fur-
thermore, Wi-Fi provides a more stable and usually faster connection.
Successfully uploaded data is automatically deleted from the smart-
phone.
2.2 Patient-centric design
This section is based on [124]1.
2.2.1 Usability considerations and interviews
The patients who participated in the studies (ref. section 2.3 and sec-
tion 2.4) were described as mainly elderly people who were not nec-
essarily acquainted with technical devices and could have mental or
physical limitations. Device handling included general control and us-
age of the smartphone, at least the usage of the Activity Monitoring
app presented here, putting on and off a wristband (Fitbit Charge HR,
since at that time, the Everion R© was not yet available) and charging
both devices once per day.
To evaluate and finalise the app user interface for the palliative care
study (ref. section 2.4), interviews were conducted with 12 patients
in the age of 49 to 80 years (mean: 63.5, sd:9.7), four of them were
female [124]. The interviewees could choose between various designs
1V. C. Klaas, A. Calatroni, and M. Hardegger, “Monitoring Patients in Ambulatory
Palliative Care: A Design for an Observational Study,” Wirel. Mob. Commun. Healthc.,
vol. 192, pp. 207–214, 2017
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(variations in size and colour of the interface elements), test different
control elements (a button and a slider) and they were also asked about
their opinion if they would like to receive feedback about their activity
through the app. The outcome has been grouped in four categories and
considered for the finalisation of the app.
App design and usability
In general, patients preferred more design solutions which reduce the
risk of misuse, e. g., bigger numbers and a confirmation dialogue before
saving the input. The question of smileys in the app design was quite
controversial and was therefore emotionally discussed, using words
like “hate” and “sweet”. All patients who liked smileys also preferred
a more colourful design. All interviewees were able to use the smart-
phone app and handle the wristband. Special needs were related to
co-morbidities, e. g., limited vision capabilities due to advanced age.
The interviews did not reveal any special needs related to the palliative
situation of the patients.
Feedback through the smartphone app
Eight out of ten patients understood the concept of feedback. Three
patients – having already experience with fitness trackers – stated
that they were interested in their physical activity data once per day.
However, they had different attitudes, considering the feedback as a
source of information or rather as an entertainment.
Motivation to use a monitoring system
Most of the interviewees were motivated to use a monitoring system
and to support research by participating in a study. Two patients suf-
fered from fatigue and found the idea of carrying the smartphone with
them also at home too cumbersome. Concerns about privacy and data
security were discussed twice. One of the fatigued patients stated that
she did not want to take an additional burden for the little time that is
left for her.
Vulnerability and sensitivity of patients in palliative care
Some of the interviewed patients were not aware of their health con-
dition and optimistic to recover from their disease. The exceptional
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situation of the interviewees in addition to a new encounter with the
previously unknown interviewer yielded in dynamic and intense inter-
views that required mindfulness and an open attitude from the inter-
viewer. Some patients used the opportunity for longer conversations.
About 25 min of each interview (50 % of the total interview duration)
were about topics irrelevant to the interviews and were considered as
a gift by the interviewer.
2.2.2 Smartphone and app
The activity monitoring app was designed based on the interview
results of section 2.2. The app consists of two parts which have been
described in detail in the following subsections:
• The patient interface provides digital questionnaires to allow
patients to rate their subjective perception of specific symptoms.
• The sensor logging module is responsible for recording and trans-
mitting signals from built-in smartphone sensors as well as for
the interface to the Everion R©, including management of the BLE
connection, requesting, receiving and recording Everion R© sensor
signals and transmitting these signals to a server.
Patient interface
The activity monitoring app used in the observational studies (ref. sec-
tion 2.3.2, 2.4) was transparent for the user:
• The app is started by the study staff before handing out the
smartphone.
• Once the app is started, it will restart automatically, e. g., after
rebooting the smartphone.
• The recording and transmission of sensor data is handled auto-
matically in the background.
The only interaction between the patient and the smartphone con-
sisted in answering the digital questionnaires. In both studies, patients
were asked to answer the digital questionnaires by a vibration alarm
in combination with showing the first questionnaire on the screen.
26 Chapter 2: The activity monitoring system and the conducted studies
The digital symptom questionnaires were designed based on the Na-
tional Comprehensive Cancer Network R© (NCCN) distress thermome-
ter (ref. section A.2.7) as visual analogue scales (VAS) with values from
0 (no symptom) to 10 (maximal symptom). In case the questionnaires
were not answered, the alarm was repeated up to 5 times at 5 minutes
intervals.
Palliative Care App Once per day, the app shows two questionnaires
in a row concerning the current subjective pain and the current
subjective distress as illustrated by Figure 2.2. The reasoning for
the frequency of the questionnaires is given in section 2.4.2.
Fatigue App 4 times per day, the app shows three questionnaires in
a row concerning the current subjective tiredness, the perceived
impact of the tiredness on patient’s daily life and about the cur-
rently performed activity. The VAS are designed as shown in
Figure , latter questionnaire lets choose from a list of 8 activities
as illustrated by Figure 2.3.
a) start screen b) value selection c) confirmation
Figure 2.2: English translation of the digital pain questionnaire as de-
ployed in German in the palliative care study. a) the empty thermome-
ter is shown in order to avoid a bias of the answers, b) the value can be
selected by touching and sliding, c) a confirmation dialogue minimises
misuse.
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a) fatigue scale b) activity selection
Figure 2.3: English translation of the digital questionnaire as deployed
in the Fatigue study. a) VAS scale, b) question concerning the currently
performed activity.
The patients in palliative care can view their current heart rate and
current step count of the current day as shown in Figure 2.4.
a) start screen b) current data
Figure 2.4: Information about current heart rate and daily step count
for the user shown by the app: a) menu to enter the screen, b) view on
the current vital and activity data.
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Sensor logging module
The recording of sensor data through the activity monitoring app has
been designed so that the smartphone can be used for at least one
day before it has to be re-charged. The smartphone logs sensor mea-
surements as described in Table 2.1. The given sampling rates are a
trade-off between battery consumption and data richness.
2.2.3 Everion R©
In the palliative care study, the Everion R© developed by the start-up
company Biovotion2, which is located in Zurich, has been deployed as
the wearable sensor for measuring vital signs. The only interaction of
the patients with the Everion R© is to wear it and to charge it. Patients
receive the devices ready to use, i. e., the devices are already paired
via BLE and fully charged. The sensor is streaming measurement data
to the tracking app automatically. The Everion R© fulfils the following
requirements:
• automatic logging and data transmission to smartphone (no
user interaction needed): the Everion R© provides streaming
to the smartphone and the option for an automatic connec-
tion/reconnection with the smartphone
• data storage to avoid data loss during lost connection: an internal
ring buffer is capable of storing the data up to 4 days
• control over access to recorded data (i. e., no transmission into
any manufacturer cloud): a developer SDK that allows to fully
control the sensor through a smartphone app.
• accurate measurement of the heart rate: It performs measure-
ments as specified in Table 2.2. Biovotion has evaluated and doc-
umented the measurement accuracies.
• at least consumer CE mark: approval as medical device (class 2)
in Europe by a notified body and in the United States of America
(USA) by the FDA.
2http://www.biovotion.com/
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Table 2.1: Sensor modalities recorded by the smartphone. The sensor
type is given in the description column of the table. (This table has
been adapted from [125].)
Modality Description Sampling Rate
Physical Activity Changes in physical behaviour can be related to pro-
gression of disease or worsening of symptoms. The
sampling rate is controlled by Android and varies de-
pending on the usage.
Accelerometer 40 Hz
Barometer 2 Hz
Magnetometer 10 Hz
Location Location provides frequency and duration of visited
places and unveils changes in user’s behaviour, in
particular his social interactions [126], which are also
known to be a health indicator [127].
GPS every 3 min
Wi-Fi every 20 s
Social Activity Social behaviour can be related to changes in the dis-
ease [127].
Phone call statistics once per day
App usage statistics once per day
Battery level, indicator for phone usage at change
Emotions Phone calls are recorded and encrypted
for later voice analysis.
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2.2.4 Server
The back end consists of a web server that receives the data and stores
them in a storage accessible via Secure File Transfer Protocol (SFTP). As
marked in Figure 2.1, the web interface for physicians can be designed
based on the outcome of this work in the future.
2.3 Pre-study: Activity monitoring of fatigued cancer sur-
vivors
A pre-study with seven fatigued cancer survivors was conducted from
May 2016 to January 2017. The feasibility study targeted participants of
a completed study conducted by the psychiatry ward of the University
Hospital Zürich [128].
The study protocol with all necessary documents including in-
formed consent, forms and paper questionnaires for the patients has
been approved by the local ethics committee (Kantonale Ethikkom-
missision Zürich) as an amendment to the study with the number
KEK-ZH-Nr. 2012-0563.
2.3.1 Patient recruitment
Participants had to fulfil the following inclusion criteria:
• Aged > 18 years
• mid to severe fatigue, i. e., FACIT-F ≤ 30, ref. section A.2.8
• willingness to use the provided smartphone
• successful briefing how to use the smartphone and activity mon-
itoring app
• signed informed consent
Excluded were patients with a relevant cognitive impairment or se-
vere depression assessed by M.I.N.I, a validated measure to assess
psychiatric clinical pictures.
Patients were recruited by phone calls during which they were:
• explained the study concept and goal
• asked to participate in the study
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• tested for eligibility, i. e., tested for fatigue FACIT-F and depres-
sion (M.I.N.I)
The results of patient recruitment are described in detail in sec-
tion 4.2.
2.3.2 Study Procedure
Baseline
Interested patients were either visited at home or met at the university
hospital or another place convenient for them. They had to fill out and
sign a general and informed consent. Participants have been provided
with a smartphone (Samsung Galaxy S5) with the pre-installed activity
monitoring app and equipped with a prepaid SIM-card, a smartphone
charger and a smartphone belt or pocket depending on their needs.
After introducing them to the app and, if necessary, to the smartphone,
they had to show that they are able to handle the device. If they had
no Wi-Fi at home, they receive a Wi-Fi hotspot as well.
Study period
Naturally, the participants had the possibility to contact the study team
at any point of time.
The first week. On the third day after start, any upcoming questions
concerning the devices or the study were clarified during a home visit
or phone call.
Digital questionnaires. Four times per day (random in fixed time
windows), the participants were notified via smartphone vibration
alarm to answer the digital questionnaires. The frequency of four times
per day was chosen as a trade-off between a comprehensive dataset
using the experience-based sampling method (ESM) [129] and a rea-
sonable burden put on the group of fatigued patients who already had
a reduced energy level insufficient to perform the activities of daily
living (ADL) [130].
Wearing the smartphone. The participants should wear the smart-
phone the all day long and charge it over night.
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Weekly interviews. Weekly interviews comprised the FACIT-F ques-
tionnaire and the usage of the smartphone.
Study end
At the end of the follow-up interval, patients filled out again the FACIT-
F and were interviewed about their experiences during the study and
their usage the smartphone and app. The interviews were conducted
in a personal meeting using the technique of a guided conversation
[131].
2.4 Activity monitoring of patients in ambulatory pallia-
tive care
The study protocol is described in detail in [132]. The study was de-
signed as an observational study, i. e., there were no planned inter-
ventions. The study protocol with all necessary documents including
informed consent, forms and paper questionnaires for the patients,
was approved by the local ethics committee (Kantonale Ethikkom-
missision Zürich) under the number PB_2016-00895. The study was
funded by the “Research in Palliative Care” program of the Swiss
Academy of Medical Sciences (SAMW) and the Gottfried and Julia
Bangerter-Rhyner Foundation, Bern, Switzerland.
2.4.1 Patient recruitment
Between 1. March 2017 and 31. March 2018, 31 patients were recruited
at the university hospital Zurich (USZ) on two wards: radiation-
oncology and palliative care. One patient passed away a few days after
being discharged from hospital and did not participate actively in the
study. The last patient finished the study on 24. Mai 2018. Inclusion
criteria were
• established diagnosis of metastatic cancer or other severe illness
• limited life-expectancy with a physicians’ guess of> 8 weeks and
< 12 months
• Karnofsky Index ≥ 50 % (ref. section A.1.2)
• ECOG ≤ 2 (ref. section A.1.1)
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• age > 18 years
Patients without sufficient knowledge of German or with a relevant
cognitive impairment were excluded.
Detailed results of patient recruitment have been described in sec-
tion 5.2.1.
2.4.2 Study procedure
Screening and baseline
Interested patients had to fill out an informed consent, were introduced
to the devices and tested if they were able to handle the devices. If they
showed their capability to handle the devices, they received a kit as
shown in Figure 2.5 consisting of
(a) a smartphone with the app, which had been installed and started
before, and equipped with a prepaid SIM-card and a charger for
the phone
(b) the Everion R©with a custom-sized band and a charger for the sensor
(c) a smartphone belt (optional)
(d) a mobile Wi-Fi hotspot including a charger, if there was not Wi-Fi
available at home
Patients who had been already using Android smartphones before,
could choose between using their own smartphone or switching to a
study smartphone (Samsung Galaxy S5 or Samsung Galaxy S5Neo).
All patients had the option to keep the study smartphone after their
study participation – also in case of an early drop-out for any reason.
Baseline. At discharge from hospital, patients filled out the Edmon-
ton Symptom Assessment Scale (ESAS), ref. section A.2.1, and the
quality of life questionnaire (QLQ-C30) of the European Organisation
for Research and Treatment of Cancer (EORTC), ref. section A.2.2.
Study period
Figure 2.6 illustrates the study procedure for included patients. Pa-
tients were asked to participate for 12 weeks. The period of 12 weeks
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a) b)
c)
d)
Figure 2.5: A patient’s tracking kit comprises: (a) smartphone with
charger, (b) arm-sensor with elastic band and charger, (c) smartphone
belt, (d) mobile hotspot with charger
was fixed as a trade-off between a comprehensive dataset and a rea-
sonable burden put on this particularly vulnerable group of patients
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who were confronted with the fact of being terminally ill.
Exceptions were early-drop outs as described in section 5.2.1 and 5.3.5.
In addition, some patients travelled for holidays during their study
participation. For the holiday period, the tracking was paused and
resumed afterwards. In these cases, the duration of 12 weeks was ex-
tended accordingly if the patient agreed.
1 6 12
Discharge 
(Baseline):
ESAS, EORTC
Day 3:
Home visit
weeks
Final:
ESAS, qualitative 
interview
weekly:
EORTC, NCCN distress, 
experiences with devices
At hospital:
Introduction to 
devices, 
informed 
consent
Daily: pain, distress 
wearing the devices
Figure 2.6: Time line for the study participation of a patient.
The first week. In the first week, a home visit was planned to ensure
the correct deployment at home (mainly configuration of Wi-Fi for
data transmission) and to provide additional support for the patient if
needed. Several patients did not return to home directly from hospital,
but stayed at a rehabilitation centre for two weeks or more. In those
cases, the home visit was made after their return from the rehabilitation
centre. Especially with younger patients, home visits were not always
necessary. In those cases, they were replaced by a phone call.
Digital questionnaires. Every day, the smartphone asked the pa-
tients via vibration alarm to rate their pain and distress on a VAS as
described in section 2.2.2. The time of the day was randomised be-
tween 8:00 and 20:00 o’clock. The time window could be adapted to
patients’ needs. Patients could also start the VAS on their own if they
wished so.
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Wearing the devices. Patients were wearing the devices all day long.
During night time, they charged their smartphone and the Everion R©
if not worn. Patients decided themselves if they were wearing the
Everion R© during night time or not. If they were wearing it during
night hours, they were recommended to charge the sensor twice per
day: after getting up and during the evening.
Weekly interviews. Once per week, patients were contacted by the
study team. They answered the EORTC QLQ-C30 questionnaire, a
questionnaire concerning their experiences with the devices in the pre-
vious week as shown in section A.2.5 and, if they rated the distress on
the digital questionnaire above 4 during the previous week, the second
part of the NCCN distress thermometer which has been described in
section A.2.7.
Study end
Thank you card. One to two weeks before the study end, patients
received a card thanking them for their participation together with two
questionnaires as preparation for the final interviews.
Final interviews. After the last study day, patients were called or
visited for a final interview comprising the ESAS questionnaire and a
qualitative, semi-structured interview following the guideline as pro-
vided in section A.2.9).
Devices. The patients were offered to keep the smartphones except
for the SIM-cards. The Everion R© sensors were collected either during
an organised appointment or home visit or the patients sent them back
by means of an already prepared box. They only needed to put the
sensor, charger and SIM-card in the box, use the stamps and adhesive
address label, close the box and bring it to the next post office.
Cases of death. Close relatives who were registered as contact per-
son received a condolence card. The mode and timing of returning
the devices (excluding the smartphone) by relatives was organised
depending on the needs of the bereaved.

3
Feature Extraction
This chapter describes the feature extraction pipelines for both studies. The
pipelines take as input the raw text files as received by the web servers and give
regularly sampled series of features as output. Feature extraction is necessary
for the later performed analysis.
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3.1 Goals and overview
Before classifying or clustering unknown data, it is favourable to ex-
tract features from raw signals as input for the subsequent machine
learning and statistical methods. Deriving features from raw values on
sliding windows has the following benefits:
• Possibility to reduce the data amount (samples) by reducing the
sampling rate with sliding window technique: since many al-
gorithms are worse than linear in computational complexity for
training, e. g., the computational complexity of a kernel SVM is
quadratic in the number of samples
• Adding information about context: by deriving values using a
sliding window, features contain information about the tempo-
ral context. Not the absolute value of a signal is used, but statistics
over several samples. For example, zero crossing rate, variance
and frequency based features give information about the dy-
namics of the signal, the mean on a sliding windows leads to
a moving average that is a finite impulse response filter (FIR)
filter to smooth the signal by eliminating fluctuations within a
window.
For the data analysis of the two studies which were introduced in
Chapter 2, a feature extraction pipeline was established. Differences are
specified accordingly in the subsections. The context for the feature ex-
traction pipeline is illustrated in Figure 3.1. For data from both devices,
the smartphone and the Everion R©, the same preprocessing steps have
to be applied. Naturally, the implementation of signal preprocessing
is device and sensor modality specific and therefore described in the
subsequent sections as annotated in Figure 3.1.
The feature extraction pipeline comprises several steps as illus-
trated in Figure 3.2. First, the raw data from the sensor signals as re-
ceived by the web severs (one for each study) is preprocessed to obtain
data with constant sampling frequencies. The output data can contain
missing values. For example, if the smartphone is in flight mode, it
does not measure and store GPS and Wi-Fi signals.
This chapter is structured according to this pipeline: the following
two sections describe the data preparation consisting of preprocess-
ing, cleaning and basic feature extraction steps for the signals of both
devices followed by the final feature extraction. The extracted features
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Feature Extraction
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raw
smartphone
Data Analysis
Data Preparation
Everion
(Chapter  3.3)
Chapter 3
Figure 3.1: Feature extraction pipeline – from raw sensor signals to
features ready for data analysis: This chapter describes the performed
steps to transform raw sensor signals to input data for analysis meth-
ods. Double lines identify output of feature extraction.
are analysed in the subsequent chapters. Chapter 4 presents the anal-
ysis of the fatigue study data and uses only the smartphone features,
whereas Chapter 5 presents the analysis of the palliative care study
data and uses features of both wearable devices.
3.2 Preparation of the smartphone data
The smartphone data was processed for both studies (ref. sections 2.3,
2.4) in the same way: the smartphone data comprises two categories
of data, namely pseudo-continuously sampled data and data recorded
only when triggered by events, e. g., phone calls and self-reports. Some
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Feature 
extraction
Figure 3.2: Feature extraction pipeline for both devices with three levels
of features: (b) basic with sampling rate depending on feature, (h)
hourly sampled, (d) daily sampled.
sensor modalities (acceleration, GPS, Wi-Fi) need an additional infor-
mation extraction step, e. g., adding information like on-/off-body la-
bels or clustering labels for location signals. These are described in
detail in the following subsections as indicated in Figure 3.3.
In case of recorded phone calls (voice), the analysis could not be
continued in order to respect data privacy of the patients. Nevertheless,
section A.3.1 shows the possibilities and challenges for unsupervised
learning given by the collected (completely unlabelled) dataset.
The Tables 3.1, 3.2 specify the recorded smartphone sensor signals
in detail.
3.2.1 Preprocessing of smartphone data: re-sampling and cleaning
of continuous signals
Since Android is not a real-time operating systems, the sampling rate is
not constant and due to high processor load or low battery state, sam-
ples (or measurements) may be dropped. For further analysis, e. g.,
in frequency domain, many methods require a uniform sampling rate
and gap-less data. To achieve a uniform sampling rate, the data is re-
sampled and gaps up to a certain length are interpolated. Longer gaps,
e. g., an hour of missing acceleration data, are treated as missing data.
The re-sampling frequency and the tolerated gap length depends on
the sensor modality. Table 3.3 shows the distribution of the different
observed sampling rates, to which frequency they are re-sampled dur-
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Figure 3.3: Data preparation of smartphone signals. Dashed lines iden-
tify input data, double lines identify the output of the data preparation,
grey parts (voice features) were not performed for all patients (ref. sec-
tion A.3.1).
ing preprocessing and up to which length gaps are filled by Piecewise
Cubic Hermite Interpolating Polynomial (PCHIP) interpolation. The
distribution of the sampling intervals was determined experimentally
based on one day of test data. The re-sampling frequencies were chosen
according to the specification of Android. In general, down-sampling
was preferred to up-sampling in order to not add synthetic informa-
tion (i. e., values that were not measured). Interpolating gaps up to a
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Table 3.1: Overview over the smartphone sensor modalities that are
recorded continuously.
Value Unit Description
Accelerometer (acc)
datetime ms Coordinated Universal Time (UTC)
time in ms from 1970-01-01
x m s−2 acceleration in x-axis
y m s−2 acceleration in y-axis
z m s−2 acceleration in z-axis
Barometer (baro)
datetime ms UTC time in ms from 1970-01-01
p mbar ambient air pressure
Magnetometer (mag)
datetime ms UTC time in ms from 1970-01-01
x µT strength of geomagnetic field along x-
axis
y µT strength of geomagnetic field along y-
axis
z µT strength of geomagnetic field along z-
axis
Battery (bat)
datetime ms UTC time in ms from 1970-01-01
batlevel % battery charging level
GPS (loc)
datetime ms UTC time in ms from 1970-01-01
long ◦ Longitude coordinate
lat ◦ Latitude coordinate
q_loc m Accuracy: radius denoting the circle
having a probability of 68 % that the
real coordinate is lying in it
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Table 3.1: Overview over the smartphone sensor modalities that are
recorded continuously (continued).
Value Unit Description
Wi-Fi (wifi)
datetime ms UTC time in ms from 1970-01-01
ap1 – Media-Access-Control address (MAC)
address of access point i found during
Wi-Fi scan
rssi1 dBm detected signal level (RSSI) of access
point i
. . .
apn – MAC address of access point N found
during Wi-Fi scan
rssin dBm detected signal level (RSSI) of access
point N
certain size has the advantage that the input data for subsequent steps
is less segmented and consists of more regular time series. The gap
size threshold is determined as a trade-off between the aim of regular
time series and the aim of not adding artificial information.
Furthermore, the raw data files contain also duplicates due to re-
peated data upload. Duplicates are identified by the timestamps and
only the first values of such sets with identical timestamps are kept.
3.2.2 Processing of the acceleration signal
On-/off-body detection from smartphone data
The on-/off-body detection for the smartphone is adapted from Choi
et al. which is based on non-zero counts (nczs) [133]. A non-zero count
is a sample that is sufficiently different from the window mean. The
algorithm of Choi was designed to detect off-body for wearables that
are attached to the body with the single purpose of logging. However,
a smartphone usually is not just attached to the body, but also used
with the hands. To take this difference into account, the algorithm
parameters are adapted to the values as listed in Table 3.4.
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Table 3.2: Overview over the smartphone sensor modalities that are
recorded when triggered by an event. A “–” denotes that a measure-
ment variable is unit-less.
Value Unit Description
Questionnaires (quest)
datetime ms UTC time in ms from 1970-01-01
Pain – VAS 0 to 10
Distress – VAS 0 to 10
Fatigue – VAS 0 to 10
Interference – VAS 0 to 10
Activity – a value out of: relaxing, multimedia,
personal hygiene, housework, eating,
socialising, hobbies, other
Phone call statistics (call)
datetime ms UTC time in ms from 1970-01-01
duration s duration of call
partner – encrypted number of communication
partner
type – flag denoting if the call is incoming or
outgoing
success – flag if the call was answered or not
App usage statistics (app)
datetime ms UTC time in ms from 1970-01-01
name1 – process name of running app 1
. . .
nameN – process name of running app N
Phone calls audio (voice)
datetime ms UTC time in ms from 1970-01-01
audio – encrypted audio file
Acceleration data is processed per patient and day. Figure 3.4 il-
lustrates the off-body detection steps. The feature ncz is calculated on
rolling windows of length of 1 min by applying the formula count. If
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Table 3.3: Examination of Android sampling intervals based on one
day of data, re-sampling frequency to which data is re-sampled
and length of gaps up to which gaps are interpolated. “–”: no re-
sampling/interpolation
Sensor Intervals Amount Re-sampling Gap size
[second] [%] frequency [Hz] [second]
Accelerometer 40 Hz 0.025 76.6 40 0.5
Accelerometer 50 Hz 0.02 23.4 40 0.5
Magnetometer 10 Hz 0.0998 100 10 0.5
Barometer 5 Hz 0.1747 80.6 5 2
Barometer 5 Hz 0.180 19.4 5 2
Wi-Fi 20 100 – –
GPS 180.5 100 – –
Table 3.4: Parameters for on-/off-body detection.
Parameter Unit Value Purpose
Time Interval
TI
min 1 basic window size
Sensor
Threshold
Tg
g 0.06 not count noise as non-zero
Non-Zero
Count
Threshold
Tnzc
counts
min 100 consider small phone interaction
(check time) as off-body
Consecutive
Non-Zero
Counts Wnzc
– 10 reduce false off-body detection and al-
low frequent short usages of the phone
Artifactual
Movement
Interval IAM
min 0 allow up to IAM consecutive on-body TI
in off-body period
Up/Downstream
Window
WUpDown
min 10 keep on-body label if there is more in-
teraction with the phone within a win-
dow of size WUpDown
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ncz > Tnzc a window is marked with 0 which stands for off-body. To
avoid that a short interaction with the smartphone, e. g., grabbing it
from the table to check the time or an incoming message, is considered
as on-body, the non-zero count threshold Tnzc is set to a larger value
than in the original implementation. Similarly, to avoid that a single
time interval with little movement is marked as off-body, there have to
be Wnzc off-body time intervals in a row in order to keep the label off-
body. However, the value of 10 min takes into account that one tends
to look at the phone for short periods of time, e. g., to check messages.
Setting the artifactual movement interval IAM = 0, on-body time inter-
vals are not ignored. The size of the Up/Downstream window of 10 min
allows that the time between regular interactions with the phone (e. g.,
check of messages every 15 minutes) is counted as off-body, whereas
interactions longer than a minute are counted as on-body time.
Evaluation of smartphone on-/off-body detection. On a test dataset
consisting of two test subjects and in total over 5 days of continuous
data, the on-/off-body detection yields a F1-score of 0.96. Hence, the
on-/off-body detection is applied to the collected smartphone data as
a cleaning step.
Step detection from smartphone acceleration data
The step detection based on the acceleration signal recorded by the
activity monitoring app on the smartphone is based on peak detection
and realised as follows: the euclidean norm of the 3-axis signal is
filtered using a low-pass FIR-filter with a cutoff frequency of 4 Hz. The
filtering step prevents from detecting noise as peaks. With the chosen
cutoff frequency, step frequencies can pass the filter and noise is filtered
out [134].
On the result, periods with walking are identified based on the zero-
crossing rate on a window of 256 samples: if the detected gait cycle
frequency lies between 0.5 Hz and 2 Hz, the window is labelled as
“walking”. The filtered signal is input for the peak detection algorithm
of Duarte [135]. Detected peaks that lie outside of “walking”-windows
are ignored and the “peak” label is removed. The number of steps per
second is then defined as the number of peaks in a window of one
second. An example is given in Figure 3.5.
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t
a)
off-body TI
0 if Wncz with consecutive 
off-body (IAM = 0)
t
TI: 1 min
t
Wnzc: 10  min
b)
 nb. ncz
# ncz > Wnzc
0 0 if #nzc < Tncz
t
0 10...
01 ...
x
x
xx
x
artifactual movements
t
WUpDown: 10  min
c)
t
0 10...
00 ...
0 ... 0
0 0...... ...
...
0 if in WUpDown around on-body TI 
only off-body TI
t
00 ...0 0...... ...
minimum(wnzc,wUpDown)
wncz
wUpDown
wncz
...
0 means off-body (final result)
UpstreamDownstream
Figure 3.4: Smartphone on-/off-body detection. a) A Time Interval TI
is marked with 0 if its non-zero count (nzc) is lower the threshold Tnzc;
b) a window Wnzc is marked with 0 if all TI in this window are marked
with 0; c) a window Wnzc marked with 1 is set to if the surrounding
windows in the Up/Downstream window are all 0.
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3.2.3 GPS
As illustrated in Figure 3.3, the GPS data is processed in several steps
consisting of additional, GPS-specific cleaning, clustering and cluster-
ing post-processing (extraction of places). The goal is to extract high
level features based on locations such as time spent at home, number
of places visited per day, etc., since these features can unveil changes
in the smartphone user’s behaviour [126, 127].
GPS cleaning
Especially indoors, the accuracy of measured GPS coordinates is vary-
ing widely. Phone GPS sensors deliver with the coordinates a radius
to specify a circle in which the real location lies with a probability of
68 % (ref. Table 3.1). To filter the data for accurate localisation, points
with a radius > 50 m are discarded. In addition, since the studies fo-
cus on features based on places, samples that were recorded while the
subject is moving, are filtered out. Movement is detected with a speed
> 10 km h−1. This threshold is a speed that is achieved by running.
The value is chosen so that movement indoors is not filtered out. Most
patients were using other means of transport such as cars or public
transport so that moving outside is filtered out. For the patients that
walked outside, the threshold was adapted empirically in order to
keep the samples at home and eliminate moving outside. For the pal-
liative care study, samples recorded while patients were in vacations
is ignored (as is done with all sensor modalities). The other studies do
not comprise vacations or the information is not available.
GPS clustering
After cleaning, the clustering method OPTICS (ref. section 1.4.4) is
applied with the parameters minPoints = 10 and eps = 10 on the
remaining set of GPS samples. As described in section 1.4.4, OPTICS is
a state-of-the-art method for spatio-temporal clustering. OPTICS de-
livers an order of the samples according to their reachability distance,
i. e., points that are lying close together will follow each other in the or-
dering. To extract clusters from the OPTICS result, the ExtractDBSCAN
algorithm as implemented by Hahsleret al. and described in [136] is
used. The parameter eps_cl is determined manually per patient. The
clustering result is evaluated by visual inspection. Note that in order to
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keep the privacy of patients, data is plotted anonymised, i. e., without
labelled axis and without map.
Clustering post-processing
A cluster where a patient has stayed less then 30 min over the whole
study period is not considered as an important place. Therefore, clus-
ters that contain less than 10 samples are ignored since it means that
over the whole study period, a person was less then 30 min at this
place. Then, the information as listed in Table 3.5 is added to each
sample of the GPS dataset.
3.2.4 Wi-Fi
This section describes the processing of Wi-Fi data.
Wi-Fi cleaning
Data structure. The recorded Wi-Fi signals are stored in a table where
a row is resulting from one Wi-Fi scan (i. e., one sample) and each
column provides the space for the RSSI values of one access point.
Filtering for home signals. The Wi-Fi signals were analysed with the
goal to reveal information about patients’ activity at home. Therefore,
in addition to the previously described pre-processing step for contin-
uous smartphone sensor signals, the result of GPS analysis (isHome) is
used to keep only Wi-Fi samples that are recorded at a patient’s home.
This filtering leads to columns containing only missing values (NA).
Such columns are deleted.
Filtering out erroneous signals. Examination of the Wi-Fi signals
recorded by Android smartphones show periods where the Wi-Fi scan
freezes, i. e., it does not update the scan result. This observation is
illustrated in Figure 3.6.
These periods with invalid data are filtered out by applying the
rule
∀i, 1 ≤ i ≤M : RSSIAPij − RSSI
APi
j+1 = 0 =⇒ deleteRSSI j+1
with M the number of AP.
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Table 3.5: Information added to the GPS dataset.
Name Symbol Unit Calculation
Cluster
label
cli – Unique number identifying the cluster
a sample (i = 1, . . . ,M, with M the num-
ber of remaining clusters)
Cluster
cen-
troids
ci (◦,◦) for each cluster cli containing points
p j = (lat j, long j), j = 1, . . . ,Ni, with Ni
the number of samples of cli, ci =
(lati, longi) with lati =
∑Ni
j=1 lat j
Ni
and
longi =
∑Ni
j=1 long j
Ni
Home clH, cH –, (◦,◦) For the palliative care study, the home
addresses are available and therefore
used to identify the home cluster. For
all patients, the home cluster is the
largest cluster in terms of number of
samples it is containing. Hence, the
heuristic “largest cluster” can be used
to reliably identify the home cluster clH
and the home centroid cH
distHome DH m, km For each sample p, the distance from
home is calculated using the haversine
distance [137]: DH = haversine(p, ch)
isHome isHome – Each sample is flagged by TRUE/FALSE
if it is at home or not using the rule:
isHome = DH < 50 m. Note that the
threshold is the same as the accuracy
limit chosen in section 3.2.3.
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Differences of timestamps show no missing values
Figure 3.6: Stuck Wi-Fi signal. The straight lines consist of identical
RSSI values for each AP.
Replacing missing values. Since the used methods cannot handle
missing values, NA values are replaced by the minimum value sub-
tracted by 1, i. e., min(RSSIi, j) − 1.
Wi-Fi clustering
The goal of Wi-Fi clustering is to extract situations out of the recorded
Wi-Fi data. These situations are influenced by the room a smartphone
user is staying in, the position of the smartphone and the position
of present persons. Hence, these situations unveil behaviour or be-
havioural changes of a smartphone user at home.
Toy dataset. For the design of the Wi-Fi clustering algorithm, a test
dataset was recorded comprising two places (home and university)
with 4 rooms, 6 rooms respectively. The second dataset was recorded
on two days with the purpose of having a realistic scenario. In addition
to the recording of the phone, the ground truth (in which room the
phone is located) was logged manually. Figure 3.7 gives a schematic
map for the second data set.
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Figure 3.7: Schematic of the rooms that are contained in the datasets.
Feature extraction. For the clustering, on the development dataset
as well as on the patient dataset, mean and standard deviation are
calculated as features on sliding windows of 6 samples (i. e., 2 min)
with an overlap of 5 samples. Note that sliding windows respect data
gaps greater than 40 s (2 samples), i. e., sliding windows are calculated
on segments between such data gaps.
Clustering. Two clustering algorithms are compared for the situation
detection task: GMM (Gaussian Mixed Model) and k-means. The GMM
does not require to know the number of clusters in advance. It is run
with different parameters and the best model is selected using the BIC
(Bayesian Information Criterion).
Result on development dataset. To evaluate the clustering result
of the development dataset, the adjusted Rand index [138] is used to
measure the overlap of predicted and actual label sets. In addition, two
graphical representations show in more details the clustering perfor-
mance. Figure 3.8 shows the predictions of different clustering methods
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and the actual labels over the time for the dataset that contains four
rooms. It reveals that part of the mismatch between actual labels and
clustering result is at the transition between rooms. One room (Room
A), is separated in two rooms, which is explainable by the fact that the
phone was for some time in the pocket and for some time on the desk.
Furthermore, both, k-means and GMM mix rooms that are adjacent.
Using multi-dimensional scaling (MDS), it is possible to project the
high-dimensional room of AP signal strengths on a two-dimensional
surface while keeping the euclidean distance, i. e., points with a large
euclidean distance in the original vector space will also have a large
euclidean distance in the projection. Figure 3.9 shows the MDS of the
cluster centroids of the ground truth, GMM and k-means confirms
the conclusion drawn from Figure 3.8, showing that the centroids of
k-means are closer to the ground truth than the centroids of GMM.
Although the clustering is not sufficiently precise in order to distin-
guish accurately between different rooms, the centroids are close to the
ground truth. However, the meaning of the clustering can be extended
to situations and the number of clusters can be used as a measure for
indoor activity.
3.2.5 Preprocessing of event triggered modalities
The collected files containing the data of questionnaires, call statistics
and app statistics are parsed, duplicates are removed and the resulting
data structures efficiently stored as data frames.
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3.3 Preparation of the Everion R© data
As described in Chapter 2, the Everion R© sensor was applied only in the
palliative care study. The Everion R© sensor transmits the measured data
in several messages. The content of these messages is described by the
following tables. For some measurements, the Everion R© delivers also
an estimation of the measurement accuracy. Table 3.6 describes the first
part of vital measurements based on the PPG sensor as well as values
derived from the 3-axis accelerometer. Table 3.7 gives the second part
of vital measurements based on the PPG sensor. The measurements
listed in Table 3.8 come from physical sensors (temperature, GSR and
barometer). Table 3.13 shows the information sent for IPI. Since due
to the nature of the signal, IPI is not sampled at a fixed frequency,
but the timestamps of the measurements depend on the measurement
value, the message format differs from the other messages and the data
processing is described separately in section 3.3.4.
3.3.1 Preprocessing: re-sampling and cleaning of Everion R©signals
With each connection and reconnection of the Everion R©with the smart-
phone, the internal clock of the Everion R© is synchronised. This is nec-
essary because the internal quartz based clock has a limited accuracy
and is a bit too fast compared to UTC: from a recorded test data set, a
sampling frequency of 1.04 Hz was extracted. The sampling frequency
that is higher than the resolution of measurement timestamps of 1 s,
lost messages and a wearing time that is less than 24 h per day lead to
four types of timestamp-counter anomalies in the data:
1. duplicates. There are timestamp duplicates from different mea-
surements, because the actual sampling frequency is about
0.96 Hz.
2. negative gaps. Having an Everion R© signal sorted by the message
counter, there appear negative time gaps due to time synchro-
nisation triggered by the smartphone (changing the sensor time
back-wards).
3. positive gaps. A continuation (i. e., increment by 1) of the counter
with a positive gap in the time > 2 s indicates a discontinuation
in the measurement, e. g., because the sensor was not worn.
4. counter gap. A gap in the counter values indicates lost messages.
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Figure 3.10: Preprocessing of Everion R© signals. Dashed lines identify
input data, double lines identify the output of the preprocessing.
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Table 3.6: Data of vital 1 message as received by the Everion R©; Q-Value
gives the range of the measurement quality as well as the threshold to
accept a measurement as valid. “–”: no unit/no Q-value
Value Unit Q-value Description
datetime s – UTC time in ms from 1970-01-01
cnt – – message counter that identifies the true
order of the measurements.
HR bpm 0 to 100
(50)
heart rate
SpO2 % 0 to 100
(50)
the level of oxygen saturation in the
blood
BLPW – – indicator for rhythmic and shape of the
blood pulse wave which is related to
HRV and stress
BLPE – – skin blood perfusion depends on skin
temperature and a good level is neces-
sary for accurate measurements
act – – activity index in the range of 0–255
based on acceleration
class – 0 to 100
(50)
activity class 0–8 denoting activities,
e.g., resting, walking etc.
steps steps s−1 – the step count per second
Figure 3.11 illustrates all four anomalies. During preprocessing,
duplicate samples are identified by identical message counter and only
first values are kept. Note that duplicate timestamps do not necessarily
imply duplicate samples. A re-sampling algorithm corrects negative
time gaps. A detailed description of the algorithm can be found in
section A.3.2.
3.3.2 Cleaning for high measurement quality, on-body data and
awake data
This section describes the cleaning procedures for Everion R© data.
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Table 3.7: Data of vital 2 message as received by the Everion R©; Q-Value
gives the range of the measurement quality as well as the threshold to
accept a measurement as valid.
Value Unit Q-value Description
datetime s – UTC time in ms from 1970-01-01
cnt – – message counter that identifies the true
order of the measurements.
HRV ms 0 to 100
(50)
the RMSSD derived from the HR
RR bpm 0 to 100
(50)
the number of inhale-exhale cycles per
minute
EE kcal s−1 0 to 100
(50)
energy expenditure
Table 3.8: Data of physical message as received by the Everion R©;
Q-Value gives the range of the measurement quality as well as the
threshold to accept a measurement as valid.
Value Unit Q-value Description
datetime s – UTC time in ms from 1970-01-01
cnt – – message counter that identifies the true
order of the measurements.
(skin)
temper-
ature
(temp)
◦C – skin temperature, after transformation
Temp
1000
galvanic
skin re-
sponse
(GSR)
kΩ – Galvanic skin resistance (impedance),
after transformation Phase×256+Amplitude3000
bar mbar – Atmospheric air pressure
Validity of samples
HR, SpO2, Activity class, EE and RR are measurements for which
the Everion R© itself delivers an estimation of the measurement qual-
ity. Based on these Q-values, the samples are tagged with “valid” or
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Table 3.9: Data of IPI message as received by the Everion R©; Q-Value
gives the range of the measurement quality as well as the threshold to
accept a measurement as valid.
Value Unit Q-value Description
datetime s – UTC time in ms from 1970-01-01
cnt – – message counter that identifies the true
order of the measurements.
inter
pulse
interval
(IPI)1
ms 0 to 15
(8)
first of 39 (in one frame transmitted)
interval durations between two pulses
IPI39 ms 0 to 15
(8)
last of max 39 interval durations be-
tween two pulses
cnt
time
1
2 3
4
Figure 3.11: Anomalies of counter and timestamps appearing in the
recorded Everion R© data. 1) duplicate timestamp, 2) negative time gap,
3) positive time gap, 4) positive counter gap
“invalid” according to the rules specified in Table 3.6, Table 3.7 and
Table 3.9.
On-/off-body detection from Everion R© data
Unfortunately, under certain circumstances (shadow), the Everion R©
does not recognise when being off-body and continues measuring
(“measuring air”). Figure 3.12 gives an example of the Everion R© mea-
suring air. The Everion R© estimates a part of these measurement values
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to be of sufficient quality. Hence, these samples should be filtered out
and only measurements coming from a patient should be kept. In
such a situation of “measuring air”, the Everion R©estimates the quality
more often to be below the quality threshold than in the situation of
being on-body. This ratio of Q-values can be exploited for on-/off-body
detection.
Labelled dataset. To clean the dataset from this noise, a SVM is
trained on a manually labelled dataset consisting of 4 patients.
Table 3.10: Overview over class distributions: number of samples per
patient and label (detailed information to the patients’ participation is
given by Table 5.1)
Patient 162 Patient 183 Patient 194 Patient 216
on-body 91129 295977 164535 172806
off-body 10269 902 3192 928
awake 57262 201489 141694 162691
sleep 33839 89437 22820 10101
Feature extraction for on-/off-body detection. For on-/off-body de-
tection, the following statistics are extracted from a sliding window on
the measurement signals transmitted by the Everion R©: mean, variance,
minimum, maximum, first quantile and third quantile as well as en-
ergy. The the sliding window has a size of 33 samples with an overlap
of 11 samples. Vital signs like heart rate and skin temperature don’t
change abrupt. Therefore, a high variance in a short window of about
30 s indicates a not physiological signal behaviour and therefore was
probably measured off-body. The overlap of 11 samples was chosen in
order to reduce the data amount. For the quality Q-values, the ratio of
valid values vs. total number samples in the window is used as feature.
All features are standardised to mean=0 and sd=1.
On-/off-body classification. Training of different classifiers such as
linear SVM, SVM with rbf kernel, adaboost and random forest are
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compared following a leave-one-patient-out approach. In general, un-
balanced classes impede the classification task. Table 3.10 shows that
the classes on-/off-body are unbalanced. For each patient, the number
of samples labelled as on-body is much higher than the number of
samples labelled as off-body. The best performing classifier that gen-
eralises is the SVM with rbf kernel with performance metrics as listed
in Table 3.11. The classifier achieves a high accuracy. However, the
precision is low in three out of four patients.
Table 3.11: Classification result for on-/off-body detection using a SVM
with rbf kernel and parameters C=10, gamma=0.01; the metrics preci-
sion, recall and F1-score are calculated for the off-body class
Patient 162 Patient 183 Patient 194 Patient 216
Accuracy 0.94 0.99 0.99 0.99
Precision 0.65 0.62 0.72 0.96
Recall 0.94 0.96 0.86 0.65
F1-score 0.77 0.75 0.78 0.78
Methods for unbalanced class distributions such as Oversampling
(SMOTE), random under-sampling, feature selection using Random
Forest and manual feature selection based on density distribution plots
did not improve the classification performance. Considering the ex-
ample data and that the difference is visible at a glance, the following
reasons could cause the classification result:
• unbalanced classes
• inexact labels
Alternative approaches for on-/off-body detection. Since the la-
belled dataset show that the off-body data is less than 10 % of the
dataset, an alternative method to clean the data set from potential
off-body data was applied: a window of 1 min was considered to be
invalid if the percentage of invalid samples is greater than 50 %. The
reasoning for this approach is the following: the examination of the
labelled data set unveiled that the probability is high that the sensor is
off-body when the number of invalid samples is greater than 50 %. If
not, a maximum of 30 s of valid data is discarded wrongly. Introducing
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small data gaps can be tolerated since the analysis methods used in
Chapter 5 do not require gap-less time series. Hence, the damage of
removing some valid data by mistake is negligible.
Another approach would be to tolerate the presence of off-body
data, since the amount is insignificant.
Sleep/awake detection
This section describes an approach to detect periods of sleep during
night. The individual daytime of a patient is defined as follows: day
starts for an individual patient when he wakes up from night sleep
and ends for an individual when going to bed for night sleep. To know
which data is recorded during sleep has several advantages:
• features like step count can be set in relation to the time being
awake
• vital signs are influenced by sleeping and therefore yield in sep-
arate features for recordings during sleep and recordings during
awake time
• the awake/sleep time itself is a feature candidate
Dataset. The same labelled dataset as for on-/off-body detection is
used for sleep/awake detection. Table 3.10 gives the class distributions.
Feature extraction for sleep/awake detection. The same method is
used as for on-/off-body detection. However, feature analysis unveiled
that features should individually be selected for each patient.
Classification of sleep/awake status. A SVM with radial basis func-
tion (rbf) kernel is trained for each patient separately by taking the first
days as training data and the last days as test data. The dataset split
for each patient is listed in Table 3.12.
As for on-/off-body detection, the unbalanced classes impede the
classification task. Again, accuracy is high, but Recall is not sufficient.
Furthermore, this approach requires a partly labelled dataset for each
patient. Possible reasons are
• unbalanced classes sleep/awake
• inexact labelling (include sleep during the day)
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Table 3.12: Dataset split (patient 4 with only 6 training days with sleep
data) and classification result for sleep/awake detection using a SVM
with rbf kernel and parameters C=10, gamma=0.01
Patient 162 Patient 183 Patient 194 Patient 216
Study Days 31 96 35 72
Training Days 7 24 9 56
Accuracy 0.799 0.822 0.82 0.911
Precision 0.75 0.65 0.31 0.61
Recall 0.73 0.90 0.43 0.99
F1-score 0.74 0.75 0.36 0.76
Alternative approaches for sleep/awake. Manual labelling is a te-
dious and time consuming task, taking up to five minutes per patient
day, and re-usable solutions are preferable. Therefore, all samples are
tagged with “daytime” or “night” based on the local time of the sam-
ple timestamp in this work. For feasibility analysis, a time from 8:00
to 20:00 is considered as day and the time outside of that window
as night. For other features, there is no differentiation between day
and night since the labelling has shown that patients seldom wear the
device while sleeping.
3.3.3 Cleaning of GSR and skin temperature
The GSR sensor and the temperature sensor have an adaption phase:
when the Everion R© is put on the skin, the signals need some time until
they are reliable as shown in Figure 3.14. For example, a daily feature
calculated by the minimum value would be always too low since the
temperature values start with room temperature when the Everion R©
sensor is put on. Figure 3.13 illustrates schematically the behaviour of
the temperature signal after putting on the sensor.
The cleaning of both signals is done on basis of the temperature
signal: the temperature signal is processed segment-wise as defined by
time gaps greater than 5 minutes since the temperature signal follows
slowly abrupt changes. On each segment, a low-pass Butterworth filter
of third order with critical frequency of 0.01 Hz is applied. This filtering
step smooths the signal in order to avoid a false detection of a switched
sign of the first derivate of the signal due to noise. The temperature
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Figure 3.13: Schematic of temperature signal after putting on the sen-
sor. The temperature signal is considered to be valid when the sign of
the first derivate of the signal changes. The blue lines denote the first
derivate of the temperature signal.
signal is considered as being adapted to the skin temperature, if the
first derivate of the filtered signal changes the sign to the opposite of
the beginning ramp. A sporadically starting peak as in Figure 3.14 is
ignored. The first derivate is illustrated in Figure 3.14 by the red line
(diff).
As result, all temperature and GSR values between dashed vertical
line and solid vertical line are flagged as “invalid”.
3.3.4 HRV analysis
Cleaning of the inter pulse interval signal IPI
Physical, mental and emotional activity as well as the respiration in-
fluences the heart rate variability. As defined by [139], standardised
measurements are performed during resting [140]. To follow this rec-
ommendation, the activity measurement of the Everion R© is used to
identify resting periods.
Ectopic beats removal
The presence of abnormal beats influences HRV metrics and therefore
have to be removed prior to metrics calculation [83]. Ectopic beats are
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Figure 3.14: Skin temperature measurement showing the time of
putting on the sensor (dashed vertical line) and detected end of sensor
adaption phase (solid vertical line). Example of a typical day of one
patient. temp: temperature, diff: difference (lag 1) of the filtered signal
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removed using the algorithm as described in [141], which is able to
identify ectopic beats based only on the RR-interval signal with an
accuracy of 98% [141].
Segmentation
Standardised window lengths for calculation of HRV metrics are 5
minutes and 24 hours [140]. Due to the limited battery capacity of the
Everion R© the focus lies on 5 min windows.
Low data rate removal
Since missing values induce errors in the feature calculation, windows
with too large data gaps are discarded. The length of tolerated data
gaps is defined by a a target error for time domain features ≤ 10%. For
frequency domain features, we respect the Nyquist-Shannon sampling
theorem: since we analyse the power spectrum for frequencies up to
fHF,upper = 0.4 Hz (upper limit of HF frequency band), we determine the
Nyquist frequency as
fc ≥
1
1
2∗ fHF,upper
= 0.8 Hz
Therefore, we set the thresholds when to discard a window as
follows:
µ, SDNN, RMSSD more than 35 consecutive seconds missing [82]
pNN50 more than 5 consecutive seconds missing [82]
LF, HF, LF/HF number of samples N < 240
Feature calculation
On the remaining windows, the features as listed in Table 3.13 are
calculated.
3.4 Feature extraction
From the above described sensor modalities and processing results,
hourly and daily features are extracted. Due to different data quality
for the three studies, the feature sets vary. Table 3.14 and Table 3.15
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Table 3.13: HRV metrics extracted from the IPI signal.
Feature Unit Description
SDNN ms Standard deviation of intervals between nor-
mal heart beats
RMSSD ms Root Mean Sum of Squared Distance of inter-
vals between normal heart beats: indicator for
ability of recovery [142]
pNN50 % % normal intervals that differ more than 50 ms.
Indicator for first deterioration.
LF ms2 Signal power in the frequency band 0.04 Hz to
0.15 Hz
HF ms2 Signal power in the frequency band 0.04 Hz to
0.15 Hz
LF/HF
ratio
- The ratio is commonly used as an indicator for
stress, but controversially discussed [140]
give an overview over the extracted features and in which study they
are used.
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Table 3.14: List of extracted features from the Everion R© as used in the
following analysis; h/d: hourly or daily feature
Name h/d Statistic Description
RHR h mean resting heart rate
RRR h mean resting respiration rate
RHRV h mean resting HRV (RMSSD)
SpO2.mean h mean SpO2
SpO2.sd h sd SpO2
SpO2.min h min SpO2
SpO2.max h max SpO2
blpw.mean h mean blood pulse wave
blpw.sd h sd blood pulse wave
blpe.mean h mean blood perfusion
blpe.sd h sd blood perfusion
cnt h count nb of samples
cnt.hr h count nb of valid HR
cnt.rr h count nb of valid RR
cnt.spo2 h count nb of valid SpO2
step.cnt h count nb of steps
step.speed h mean speed (steps/sec)
step.speed.sd h sd speed (steps/sec)
step.speed.var h var speed (steps/sec)
act.zero h count nb of activity==0
act.mean h mean activity
act.sd h sd activity
act.var h var activity
act.class h mode most frequent activity class
cor.p h cor Pearson correlation between HR and act
cor.k h cor Kendall correlation between HR and act
cor.s h cor Spearman correlation between HR and act
t.max h max skin temperature
t.min h min skin temperature
t.range h max-min skin temperature
t.mean h mean skin temperature
t.sd h sd skin temperature
gsr.mean h mean GSR impedance
gsr.sd h sd GSR impedance
gsr.min h min GSR impedance
gsr.max h max GSR impedance
t.min.day d min skin temperature
t.max.day d max skin temperature
t.range.day d max-min skin temperature
ipi.mean_mean h mean ipi mean (HR)
ipi.std_mean h mean ipi sd on 5 min. window
ipi.pnn50_mean h mean PNN50
ipi.lf_mean h mean LF
ipi.hf_mean h mean HF
ectopic_mean h mean nb of ectopic beats
lf_hf_ratio_mean h mean LF/HF
ipi.mean_sd h sd ipi mean (HR)
ipi.std_sd h sd ipi sd on 5 min. window
ipi.pnn50_sd h sd PNN50
ipi.lf_sd h sd LF
ipi.hf_sd h sd HF
ectopic_sd h sd nb of ectopic beats
lf_hf_ratio_sd h sd LF/HF
ipi.mean_cnt h count ipi mean (HR)
ipi.std_cnt h count ipi sd on 5 min. window
ipi.pnn50_cnt h count PNN50
ipi.lf_cnt h count LF
ipi.hf_cnt h count HF
ectopic_cnt h count nb of ectopic beats
lf_hf_ratio_cnt h count LF/HF
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Table 3.15: List of extracted features from the smartphone as used in
the following analysis; h/d: hourly or daily feature; y: used in the study
Name h/d Statistic Description
maxDistFromHome h max maximal distance from home
sumDistOutside h sum sum of distance covered outside
sumDistHome h sum sum of distance covered at home
cntHome h count nb samples at home
cntOutside h count nb samples outside
cntCluster h count nb cluster
cntLeavingHome h count nb of times leaving home
cntComingHome h count nb of times coming home
firstLeavingHome d min time of first leaving home
lastComingHome d max time of last coming home
cntHomeDay d count nb samples at home
cntLeavingHomeDay d count nb of times leaving home
cntComingHomeDay d count nb of times coming home
firstLeavingHomeDay d min time of first leaving home
lastComingHomeDay d max time of last coming home
maxDistFromHomeDay d max maximal distance from home
sumDistOutsideDay d sum sum of distance covered outside
cntOutsideDay d count nb samples outside
cntClusterDay d count nb cluster
acc.cnt h count nb samples acceleration
cntOnbodyValid h count nb samples on-body
onbodypercent h perc percentage wearing the smartphone on-body
cntWalkingValid h count nb samples walking
walkingpercent h perc percentage of walking
acc.mean h mean norm of acceleration
acc.sd h sd norm of acceleration
acc.var h var norm of acceleration
acc.q10 h 10% quantile norm of acceleration
acc.q25 h 25% quantile norm of acceleration
acc.q75 h 75% quantile norm of acceleration
acc.q90 h 90% quantile norm of acceleration
moving h count nb samples while moving
movingPercent h perc percentage of moving
acc.steps.speed h mean smartphone steps speed (steps/sec)
acc12 d count nb samples acceleration
cntOnbodyValidDay d count nb samples on-body
onbodypercentDay d perc percentage wearing the smartphone on-body
cntWalkingValidDay d count nb samples walking
walkingpercentDay d perc percentage of walking
acc.meanDay d mean norm of acceleration
acc.sdDay d sd norm of acceleration
acc.varDay d var norm of acceleration
acc.q10Day d 10% quantile norm of acceleration
acc.q25Day d 25% quantile norm of acceleration
acc.q75Day d 75% quantile norm of acceleration
acc.q90Day d 90% quantile norm of acceleration
movingDay d count nb samples while moving
movingPercentDay d perc percentage of moving
acc.steps.speedDay d mean smartphone steps speed (steps/sec)
cnt.total.in d count nb of incoming calls
cnt.total.out d count nb of outgoing calls
cnt.succ.in d count nb of answered incoming calls
cnt.succ.out d count nb of answered outgoing calls
sum.succ.in d sum duration of incoming calls
sum.succ.out d sum duration of outgoing calls
min.succ.in d min duration of shortest incoming call
min.succ.out d min duration of shortest outgoing call
max.succ.in d max duration of longest incoming call
max.succ.out d max duration of longest outgoing call
avg.succ.in d mean duration of longest incoming call
avg.succ.out d mean duration of longest outgoing call
4
Pre-study: Monitoring
cancer related fatigue
This chapter presents the results of an observational study, conducted in
Zurich, of cancer survivors suffering from cancer related fatigue.
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4.1 Fatigue study overview
4.1.1 Goals of fatigue study
As a pre-study, the fatigue study was conducted with the following
goals:
• to test the usability of the activity monitoring app
• to gain experience in activity monitoring severely-ill patients
• to explore the collected data to gain insights into the daily life of
the patient group
4.1.2 Summary of study procedure
As already described in section 2.3, a study of 7 cancer survivors suf-
fering from CRF was conducted in collaboration with the University
Hospital Zürich. Adults with a mid-to-severe fatigue and who were
not suffering from depression were asked if they would carry and
use a smartphone for 2 to 3 weeks to record the sensor data, as de-
scribed in Table 2.1. Furthermore, they were asked to answer digital
questionnaires four times per day. They completed two VAS scales
about their currently perceived fatigue, and how much this fatigue
currently affected their daily life and the currently performed activity
(ref. Figure 2.3). At the beginning (baseline) and after each week of
study participation, patients were called to assess their level of fatigue
using the FACIT-F questionnaire (ref section A.2.8). They were also
interviewed about their experiences with the smartphone.
4.2 Study cohort
In total, 7 cancer survivors between the ages of 32 and 73 years (me-
dian: 54, sd: 15.77, 6 female) were included in the study. The study
participants are listed in Table 4.1.
4.3 Collected data and feasibility
As listed in Table 4.2, the cancer survivors participated for 2 to 3 weeks.
Patient 66 dropped out as a consequence of unstable health. She is
excluded from further data analysis. During in total 124 days, 2772
hours of data and 523 answered questionnaires were collected.
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Table 4.1: Overview on the included study participants. BL: baseline
**: value after week 1; *: drop out
Pat. Id Age Gender FACIT-F (BL)
[y]
103 32 f 22**
64 58 m 35
219 73 f 23
62 37 f 24
111 33 f 23
232 52 f 29
66* 56 f 24
Table 4.2: Overview on data completeness. Days: number of study
days; DwQ: percentage of days with answered digital questionnaires;
QpD: average number of questionnaires per day; DwS: percentage
of days with smartphone on-body; HSO: average percentage of time
when the smartphone was on-body during daytime
Pat. Days No. DwQ QpD HwS DwS HSO
Id questionnaires (WI)
103 32 127 90.6 4 739 90.6 25
64 16 53 87.5 3.3 342 100 33
219 31 121 96.8 3.9 735 100 43
62 15 61 93.3 4.1 324 100 42
111 15 62 86.7 4.1 301 100 38
232 15 99 93.3 6.6 331 100 48
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4.3.1 Wearing the smartphone
The smartphone’s acceleration signal is analysed to determine for how
long a patient was wearing the smartphone (on the body). As de-
scribed in section 3.2.2, during the pre-processing of the sensor signals,
the smartphone’s acceleration data was tagged with a label indicating
weather the smartphone was worn on-body during the recording. The
wear-index (WI) is calculated as the ratio between on-body samples
(i. e., measurement points) and the total number of measurement sam-
ples:
WI =
# on-body samples
# on-body samples + # off -body samples
Table 4.2 shows that all of the patients were wearing the smartphone
every day. However, the percentage of time per day that patients wore
the smartphone on-body is lower than 50 %. The lowest values are
explained as follows:
• Patient 64 did not follow the instruction to wear the phone also
at home.
• Patients 103 and 111 both reported that they were very tired all
of the time and were lying down for large parts of the day. When
they were resting, they did not wear the smartphone.
A WI of 100 % means that the smartphone was worn on-body for
24 h. Naturally, this is hard to achieve outside of a laboratory, as it
means the smartphone should be on the body during activities such as
sleeping and showering. Estimating 8 h of sleep and additional time
spent on personal hygiene leads to a WI of about 60 % to 70 %.
4.3.2 Answering the questionnaires
All of the patients except two filled out the questionnaires (ref. sec-
tion 2.3.2) at least 4 times per day for around 90 % of the days. Patient
66 who dropped out stated that she did not want to reflect on her fa-
tigue four times per day or being constantly reminded of her situation.
Since fatigue is a sensitive topic for her, she found it difficult to cope
with her situation when she was asked about it several times per day.
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4.4 Analysis of self-reports
4.4.1 FACIT-F
Figure 4.1 shows that four out of six patients had improved FACIT-F
values at the end of the study.
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Figure 4.1: The course of FACIT-F reports for all patients.
4.4.2 Digital questionnaires: fatigue and interference
Distribution of VAS values
Figure 4.2 shows the histogram of the reported fatigue on a VAS scale.
Peaks are visible for the even numbers (2, 4, 6, 8); in each case, the
adjacent odd numbers were selected less often compared to the even
numbers. In this pre-study, the VAS scales were labelled only with even
numbers, as shown in Figure 2.3 a). Omitting odd numbers possibly
created a bias towards even numbers.
Relation between fatigue and interference of fatigue
The two VAS scales for fatigue and interference are positively corre-
lated (r = .77, n = 523, p < .0001). Two possible explanations are
1. The higher the fatigue, the more it impacts on daily activities.
If one is less tired, it is probably easier to ignore one’s lack of
energy during activities of daily life.
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Figure 4.2: Histogram of Fatigue (VAS) shows the count of fatigue
values reported by all patients through the smartphone VAS. Peaks for
the even numbers 2, 4, 6 and 8 indicate a bias through the app design
(ref. Figure 2.3).
2. The patients could not distinguish between the two question-
naires.
Figure 4.3 shows the reported fatigue with the corresponding re-
ported interference per patient. For each reported pair, the dot size
indicates the number of occurrences of this pair in the dataset. Only
for values 1 and 2, there is an accumulation of same answers. For the
other values, the diagonal is not over-represented except for patient 64,
who had low fatigue and interference (2) or high fatigue and interfer-
ence (9) and only a few values in between. Hence, Figure 4.3 supports
explanation no. 1 (i. e., the higher the fatigue, the more it is perceived
as having an impact on daily life).
Intra-day course of fatigue
The ESM was used for collecting the digital self-reports. ESM unveiled
that fatigue is not constant throughout the day. All self-reports were
grouped according to their timestamp in order to identify patterns in
the daily course of fatigue. The day was divided into six time frames:
late night 2-6 o’clock
morning 6-10 o’clock
midday 10-14 o’clock
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Figure 4.3: Scatter plot of all digitial questionnaires per patient con-
cerning fatigue vs. interference: The dot size represents the count of a
VAS value pair. The diagonal denotes where fatigue is equal to inter-
ference.
afternoon 14-18 o’clock
evening 18-22 o’clock
night 22-2 o’clock
Naturally, there are few values available for night time (seven re-
ports in total) and late night time (one report). Figure 4.4 shows that
the perceived fatigue varies during the day. In this study, there are
different patterns present: In two patients, the fatigue increases during
the day; one patient has a decrease towards midday, followed by an
increase towards the evening that is close to the morning value, and
three patients have a constant median throughout the day, but with a
varying inter quartile range (IQR).
4.4.3 Correlation between VAS and FACIT-F
To compare the paper-based questionnaires with the VAS reports for
fatigue and interference, the median of all the answered VAS for one
week is compared to the FACIT-F value at the end of the same week.
Figure 4.5 shows that for most patients, both measurement instru-
ments show similar trends. Only for patient 62 did the VAS remain
constant while the FACIT decreased (i. e., increasing fatigue).
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Figure 4.5: The course of all patients’ FACIT-F reports over the study
period.
4.5 Correlations between sensor modalities and self-
reports
Different features, based on the recorded acceleration signal and GPS
signal of the smartphone, were tested for correlations with the VAS val-
ues concerning fatigue and the interference of fatigue. However, there
was no feature that correlated similarly in several patients. Possible
reasons for low correlations include:
• small amount of valid activity data at home
• the use of an additional smartphone is different to how one uses
one’s own smartphone
• cause and effect remain unknown: a patient could be active, and
they could feel tired afterwards because of this activity; in con-
trast to this, a patient might not be active because they feel tired
• depending on external requirements, some patients may have to
manage their daily lives, regardless of their degree of fatigue
4.6 Discussion
4.6.1 Summary of results
This pre-study showed that adult patients suffering from medium-to-
severe CRF are eligible for activity monitoring through a smartphone.
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The patients’ self-reporting via their smartphones was successful; they
reached reporting rates of roughly 90 %. However, wearing the phone
on-body at home was noted as being inconvenient or meaning too
much effort for some patients.
In assessing perceived fatigue, experience-based sampling un-
veiled information about the general course of fatigue: The rate of
perceived fatiuge varies throughout the course of the day. The patients
of this study had three different patterns. Furthermore, the VAS scales
showed similar trends to the weekly questionnaires.
4.6.2 Limitations
The pool from which to recruit patients was limited for this study. The
sample size of seven patients was too small as a result and general
conclusions could not be drawn. The study period of 2-3 weeks is not
sufficient to evaluate retention for longer periods. A longer time frame
is needed.
4.6.3 Lessons applied to the palliative care study
Experience gained through the fatigue study influenced the palliative
care study in the following ways:
• The VAS scales on the smartphone were changed to show every
possible whole number in the range from 0 to 10, in order to
avoid a bias towards even numbers.
• The smartphone belt is considered a crucial element to increase
smartphone wearability, and is, therefore, included in each pa-
tient’s kit by default.
• Patient meetings are planned with time-slots of one hour plus an
additional buffer of one hour for any unforeseen delays.
5
Monitoring cancer
patients in palliative
care
This chapter presents the results of an observational study performed on 31
cancer patients in ambulatory palliative care.
86 Chapter 5: Monitoring cancer patients in palliative care
5.1 Overview of the palliative care study
5.1.1 Goals of the palliative care study
The palliative care study was designed as an observational study with
the following goals:
• to evaluate feasibility of activity monitoring in this specific pa-
tient group
• to evaluate patients’ acceptance and usability of the wearable
devices
• to conduct a descriptive data analysis of the patient-reported
outcomes
• to conduct an exploratory data analysis of recorded sensor sig-
nals and non-elective (i. e., unplanned) hospital visits and re-
admissions
5.1.2 Summary of study procedure
As already described in section 2.4, a study with 31 outpatients in pal-
liative care was conducted in collaboration with the University Hospi-
tal Zürich. Patients selected for this study were adults with metastatic
cancer who were given between 8 weeks and 12 months to live and
who were mobile for at least 50 % of their wake-time. They were asked
if they would carry and use a smartphone and wear the Everion R© for
12 weeks in order to record the sensor data as described in Table 2.1
and 2.2. Furthermore, they were asked to answer digital questionnaires
once per day. These questionnaires comprised two VAS scales, where
patients could record their current pain and distress (ref. Figure 2.2).
At the beginning (baseline) and after each week of study participation,
patients were called to assess their quality of life using the validated
questionnaire QLQ-C30 (ref section A.2.2). They were also interviewed
about their experiences with the smartphone.
5.1.3 Performed analysis
This chapter presents the results of several analyses. Figure 5.1 outlines
the topics in this chapter. Section 5.2.1 describes the patients’ demo-
graphics. Section 5.3 presents the analysis and results concerning the
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Figure 5.1: Graphical overview on the analysis of the palliative care
study.
general feasibiltiy of the activity monitoring as well as the patients’
acceptance of it. Section 5.4 presents the outcomes of the patients’ self-
reports. Furthermore, an approach to predict emergency events using
anomaly detection is presented in the appendix in section A.6.
5.2 Study cohort
5.2.1 Study cohort
In total, 31 patients, between the ages of 39 and 85 years (mean: 61.9,
sd: 11.4, 9 female), were included in the study. Table 5.1 gives an
overview of the patients. In total, 11 patients had at least one non-
elective (i. e., unplanned) visit to hospital (ambulatory or stationary),
5 patients passed away, either during their study period or up to one
month after finishing the study., and 8 patients were using a walking
aid, i.e., a pole, crutches, a walking frame or sitting in a wheel chair.
Patient 61’s wife stated that her husband was fearful when dis-
charged from hospital and apathetic when at home. He did not wear
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Table 5.1: Overview of included patients. Gender: m – male, f – female;
Age: in years; Karnofsky: in %; SDN: number of study days; EV: day of
first emergency visit (0: no emergency visit); Death: 1 – patient passed
away; Aid: 1 – patient used a walking aid; *: passed away during
participation or shortly after.
ID Gender Age ECOG Karnofsky SDN EV Death Aid
23 m 61 2 70 106 0 0 0
55 m 66 1 80 104 2 0 0
61 m 61 1 90 NA 0 1 0
69 m 73 1 80 128 0 0 0
128 f 49 2 70 140 0 0 0
142 m 77 1 80 80 0 0 0
162* f 39 1 NA 94 5 1 0
168 f 69 1 80 108 0 0 0
192 f 57 1 80 105 0 0 0
183 m 63 2 60 97 12 0 1
187 m 52 1 90 88 0 0 0
194* m 71 1 80 148 6 1 0
193 m 78 1 80 90 0 0 0
165 m 50 2 60 38 0 0 0
216* m 81 2 60 75 8 1 1
246 m 50 1 NA 94 11 0 0
271* m 68 2 NA 85 0 0 1
277 m 51 0 NA 94 0 0 0
319 m 65 2 60 105 0 0 1
324 m 76 2 60 34 0 0 1
351 m 53 2 60 85 4 0 0
340 f 65 2 60 29 2 0 1
359 m 55 0 90 97 0 0 0
355 f 66 2 60 95 0 0 0
377 f 41 1 80 97 0 0 0
405 m 60 1 70 85 6 0 1
423 f 85 1 80 85 75 0 0
424 m 62 1 80 35 0 0 0
429 m 60 0 NA 85 0 0 0
430 f 50 2 NA 85 8 0 0
438 m 64 2 50 83 0 1 1
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the study devices and passed away a few days after discharge. Nev-
ertheless, his wife stated that he was happy and looking forward to
participating in the study. He is excluded from further analysis.
5.3 Collected data and feasibility
After preprocessing the data, as described in chapter 3, the data is
analysed with respect to its completeness. The collected amount of
valid data is different for the devices and is summarised in Table 5.2:
the analysis evaluated three tasks wearing the smartphone, wearing
the Everion R© and answering the digital questionnaires:
answering the digital questionnaires: the percentage of days at which
the questionnaires were answered (DwQ) was calculated as well
as the average number of questionnaires answered per day of the
days with at least one questionnaire answer (QpD).
wearing the Everion R©: the percentage of days at which the Everion R©
was worn (DwE) was calculated as well as the average percent-
ages of wearing time of the Everion R© during the day (HwED)
and night (HwEN).
wearing the smartphone: the percentage of days at which the smart-
phone was worn (DwS) was calculated as well as the average
percentage of wearing time of the smartphone during the day.
The following sections investigate he extent to which the patients
wore the devices. The completeness of the data from the questionnaires
is also investigated.
5.3.1 Wearing the Everion R©
Measurement quality of the Everion R©
Figure 5.2 shows the quality of the data collected by the Everion R© for
a patient’s typical day. The y-axis denotes the time from midnight to
midnight. The x-axis denotes the available measurements of the sensor.
Figure 5.2 shows that patient 23 either woke up during night or went
to bed around 1 o’clock. Indeed, in the weekly interview, the patient
stated that when he was wearing the sensor at night-time, he was
woken up by a smartphone notification, which asked him to recharge
the sensor. (The patients were advised to recharge the sensor before
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Table 5.2: Overview of data completeness as percentages. Days: number
of days being either at home or in rehabilitation; DwQ: percentage of days
with answered digital questionnaire; QpD: average number of questionnaires
per day; DwE: percentage of days with Everion R© data; HwED: percentage of
Everion R© wearing time in hours during day; HwEN: Everion R© wearing time in
hours during night; StS: 1 – study smartphone, *: exclusively; DwS: percentage
of days with smartphone on-body; HSO: avg. percentage of smartphone on-
body during daytime (wear-index); *: passed away.
ID Days DwQ QpD DwE HwED HwEN StS DwS HSO
23 106 83.96 1.71 56.6 70.9 1.33 1;0* 89.62 48.39
55 94 72.34 1.69 44.69 72.3 2.04 1 89.36 74.46
69 127 98.43 3.74 94.49 87.39 1.35 1* 100 74.21
128 125 86.4 1.2 69.6 54.68 0.76 1* 88.8 72.44
142 79 96.2 5.68 81.01 51.12 1.59 1* 98.73 41.89
162* 58 25.86 1.07 25.86 62.23 1.58 1 20.69 3.3
168 102 65.69 2.55 14.71 58.76 0.3 1 69.61 6.47
192 104 80.77 1.08 5.77 76.66 0 1* 93.27 17.53
183 96 90.62 1.52 62.5 78.37 2.08 1;0* 93.75 46.01
187 84 92.86 1.64 93.75 84.56 0.16 1* 100 78.02
194* 132 36.36 1.29 21.21 76.3 0 1 45.45 58.19
193 91 83.52 2.05 55.56 60.85 1.06 1* 90 36.34
165 36 80.56 1.48 77.78 49.49 0.78 1* 94.44 41.24
216* 67 43.28 1.34 19.12 45.6 0 1* 67.65 64.25
246 76 96.05 1.11 64.47 69.97 0.22 1 94.74 9.48
271* 85 96.47 1.37 68.24 79.19 0.27 1* 97.65 68.29
277 96 85.42 1.54 92.55 80.7 0.05 1 100 84.68
319 104 69.23 1.1 50.96 37.57 1.79 1* 89.42 83.94
324 33 45.45 1.67 33.33 65.05 0.95 1 54.55 35.65
351 61 96.72 1.08 67.21 58.3 1.52 0* 100 38.69
340 23 69.57 2.56 41.18 61.72 0.82 1 100 37.47
359 96 70.83 2.01 67.71 81.54 0 1 79.17 76.37
355 94 86.17 1.48 92.55 54.51 2.37 0* 95.74 20.4
377 80 83.75 1.21 85 55.93 2.12 1 92.5 28.32
405 71 49.3 1.03 43.94 58.16 0 0* ;1* 93.94 40.22
423 76 11.84 1.22 10.53 52.2 0.32 1 51.32 73.35
424 20 90 1.17 15 23.88 0 0* 100 29.52
429 84 92.86 1.53 63.1 83.93 0 1* 98.81 74.55
430 46 82.61 1.16 15.22 20.99 1.14 1 86.96 58.88
438* 87 56.32 1.08 78.31 62 2.23 1 84.34 63.06
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going to bed.) He put on the sensor in the morning around 9 o’clock.
Before 20:00 o’clock, he took the sensor off.
Patients cannot actively influence the measurement quality of the
Everion R© (except for correct placement), since the measurement qual-
ity depends on many factors, such as skin colour, arm movement and
blood perfusion. In general, the data quality is high throughout the
day, except for the measurement of SpO2, which is more sensitive to
artifacts introduced by movements of the arm. Only data labelled as
valid is used for the analysis in section 5.5.
Retention (Everion R©)
In total, 16 587.43 h data were collected by the arm-sensors. The bars in
Figure 5.3 show the number of patients per day that were not hospi-
talised or in vacation. The black line indicates the number of patients
in the study, and the red line indicates the percentage of patients that
have wore the sensor at a day. In total, 12 patients wore the device at
less than 50 % of the days. The patients’ main reasons for not wearing
the device included forgetting to put it on, their bad health, the fact that
they were in rehabilitation and some technical issues (mainly instable
Bluetooth connection with some devices, ref. section 5.3.5). The other
18 patients wore the device for 73.41 % of the days of the study.
The blue and green lines show the percentages of data collected
during the day (8:00 to 20:00), with a 62.5 % average for all patients,
and night hours (20:00 to 8:00) with 1.7 % average for all patients. The
majority of patients did not wear the device during night. The blue
and green lines show that the wearing time was stable over the entire
study period.
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Figure 5.2: Data completeness plot for a typical day of patient 23. Valid
data is shown in dark green and invalid (i.e., of low quality) data is
shown in light green. White denotes periods without any data (missing
values). The prefix denotes the quality value, not the measurement
value. The abbreviated names of the measurement values are explained
in Tables 3.6, 3.7 and 3.8.
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5.3.2 Wearing the smartphone
For a reliable analysis of the physical activity measured by the smart-
phone, one has to take into account that the smartphone is not on-body
all the time (e. g., when indoors, one does not usually keep the smart-
phone on-body). Off-body time does not provide information, apart
of GPS (under the assumption that the patients take the smartphone
with them whenever they leave the house). In this case, an off-body
smartphone still provides information about where the patient was
staying during the off-body time. Only one patient (424) admitted that
she is forgetful and often left the devices (smartphone and Everion R©)
at home, because she was not used to having a smartphone. In order to
make the wearing of a smartphone at home more convenient, patients
received a smartphone belt that is popular in running sports because it
is small, unobtrusive and does not move easily, even with high - sports.
Nevertheless, for some patients, it was too cumbersome to wear the
smartphone while staying at home. As swown in Table 5.2, column
HSO, patients wore the smartphone during the day (8:00 to 20:00) on
average 49.52 % of the time at on average 85.35 % of the days (column
DwS).
Figure 5.4 shows that there is no significant difference in the WI
between patients who used the smartphone as their primary smart-
phone or as their secondary smartphone during their participation in
the study. Thus, an additional (secondary) smartphone fulfils the pur-
pose of logging sensor data just as efficiently as a primary smartphone
does.
Retention (smartphone)
Similar to the retention analysis for the Everion R©, Figure 5.5 shows
that patients wore the smartphone on a constant level around 50 %
between 8:00 and 20:00 over the whole study period.
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Figure 5.4: Comparison of the mean on-body percentage during the
day of patients who had just one smartphone (first), switched between
phones (partly first) or used the study smartphone as a second smart-
phone next to their private one (second). The error bars denote the
95 % confidence intervals, showing that the difference of 5 % between
the use of the study smartphone as the main phone or as a secondary
phone is insignificant.
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5.3.3 Answering the questionnaires
All patients could use the smartphone app to answer the digital ques-
tionnaires, as Table 5.2 shows. In total, 3348 answers for the digital
questionnaires were collected. The patients filled out the question-
naires for, on average, 72.75 % of the days they were at home or in
rehabilitation. In total, 3 patients answered for less than 40 % of the
days. Table 5.3 shows possible reasons for the low answering rates of
these patients. Excluding these 3 special cases leads to a response rate
of 78.91 % for 90 % of the patients. Figure 5.6 shows that the retention
over time is on a constant level over the whole study period.
Table 5.3: Reasons for low VAS answering rates of three patients; Days:
percentage of days with VAS answers; *: passed away
ID Days Situation
162* 25 This patient underwent several emergency visits and the
tracking was ’too much’ in combination with her rapidly
worsening health condition.
192 36.84 After an unplanned stay in a hospice, her study participa-
tion was restarted.
423 11.54 The oldest participant described herself as being very for-
getful.
Remarkably, 13 out of 30 patients filled out the questionnaire on
average more than 1.5 times per day. Patient 142 stated that he wanted
to fill it out every time he feels a change and did so on average 5.68
times per day.
5.3.4 Weekly interviews
Completeness of weekly interviews
As described, the patients were called once per week. It was the re-
sponsibility of the interviewers to call, so that the patients were not
obliged to remember the interview appointments. In general, the pa-
tients were easy to contact. In total, 251 out of 301 weeks are complete
(i. e., 83 %). Patient 424 is excluded from the analysis of the weekly
interviews because his health deteriorated quickly, and he was unable
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to speak on the phone. Details about the completeness of EORTC are
provided in Table 5.4.
Table 5.4: Completeness of QLQ-C30 scores for baseline (i.e., at dis-
charge from hospital), final and weekly interviews of all patients. The
absolute numbers of complete, incomplete and missing questionnaires
are provided in three columns.
type complete incomplete missing
baseline (BL) 23 4 3
final 18 0 12
interview 251 19 31
Reliability of EORTC QLQ-C30
The reliability of the scores is tested with Cronbach’s alpha [143]. This
metric provides the internal consistency of scores that are measured by
multiple Likert-type scales and items. In general, a threshold of α = .8
is accepted. The QLQ-C30, as shown in section A.2.2, comprises 30
questions that build 15 scores. In total, nine of these scores are com-
posed of more than one item and are, therefore, tested for reliability.
The reliability of each score is estimated on the basis of all available
questionnaire answers of all study participants. The instructions con-
cerning how to calculate the scores are given in [144].
Table 5.5 shows the calculated Cronbach’s alpha values for the
QLQ-C30 questionnaire results that were collected during the per-
formed study. The scores for concentration/focus (CF), family and
friends (S) and nausea (NV) do not fulfil the threshold. The analy-
sis also revealed that dropping various items would not increase the
reliability of these three scores. As a result, these three scores should
not be used in future analysis of this data set. However, the global
health status (QL2) can be used for further analysis of this data set.
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Table 5.5: Reliability of QLQ-C30 scores using Cronbach’s alpha.
*: low reliability
Score Alpha Score name
QL2 0.89 global health status/ QoL
PF 0.88 physical functioning
RF 0.92 role functioning (work and leisure)
FE 0.81 emotional functioning
CF* 0.79 cognitive functioning (concentration/focus)
S* 0.62 social functioning (family and friends)
FA 0.82 tiredness
NV* 0.75 nausea and vomiting
PA 0.92 pain
5.3.5 Evaluation of the feasibility of activity monitoring in the study
cohort
Duration of study participation
Most of the patients participated for the entire study period (12 weeks)
and agreed to compensate for breaks due to vacation, rehabilitation or
re-hospitalisation by continuing after week 12. Patients who dropped
out had to do so mostly due to health reasons.
Only two patients (324, 351) aborted the study due to reasons other
than severe worsening health. Patient 324 had to deal with an unstable
Bluetooth connection. The reasons for the drop-out of patient 351 are a
combination of bad health condition (2 unplanned re-hospitalisations
in 4 weeks) with difficult device handling due to unstable Bluetooth
connection.
Feedback concerning the Everion R©
In general, the feedback concerning the Everion R© was positive: The
patients stated that it did not require a lot of effort to wear it and that
it did not disturb them. Many patients would have participated for a
longer study period. Reactions from the environment of the patients
were mostly curiosity. One patient discussed the topic of data security
with others.
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Only two patients complained about the Everion R©. The first patient
said that the band was uncomfortable and restricted his arm. This pa-
tient was obese and needed a very large band. The issue was reported
to Biovotion, who reported that they were working on an improved
design of the elastic. Another patient experienced difficulties in putting
on the sensor as he had to use crutches when standing and moving.
One patient experienced an allergic reaction, diagnosed as a contact
allergy by his dermatologist (probably on the GSR sensor field). De-
spite this, the patient continued to wear the Everion R©. He replaced the
elastic with a bigger elastic. The allergic reaction healed and did not
show up again.
Smartphone usage
All patients – apart from two patients who experienced difficulties to
use a smartphone in general – were able to use our app and and the
Everion R©.
Patient 355 received her first smartphone when she began to par-
ticipate in the study. Using it for general things, such as making calls
and sending texts, was difficult for her. She stated that she would have
given up on the study if not for several home visits.
The oldest participant, patient 423, was an 85 years old woman
with hyperthyroidism. She wanted to abort the study because of her
worsening health and because of the difficulty she experienced in using
the smartphone.
Reasons for not wearing the devices
Common reasons for not wearing the devices included personal hy-
giene, sleep, the need to charge the devices or not having the smart-
phone on-body while at home. As well as this, worsening health con-
ditions among some patients led to them not wearing the sensor, espe-
cially in cases of re-hospitalisation. In the case of patient 423, she forget
to take her device with her on certain days, so some days are missing.
5.3.6 Which patients are eligible for activity monitoring?
In general, all of our included patients could handle the devices. In
terms of data completeness, new smartphone users were highly capa-
ble. However, in combination with forgetfulness, data completeness
dropped significantly (e. g., patient 423). The second obstacle was the
102 Chapter 5: Monitoring cancer patients in palliative care
worsening of symptoms: To a certain extent, patients could handle
the additional tasks of the stufy. However, when their health condi-
tions worsened, the patients had to deal with its associated issues.
This meant that they stopped wearing the device or stopped tracking
entirely.
5.4 Descriptive statistics of self-reports
5.4.1 Edmonton Symptom Assessment Scale
At the beginning of the study (baseline) and at the end of the study
(final), the patients reported the ESAS (section A.2.1). Here, ’baseline’
refers to the day of discharge from hospital and ’final’ refers to the
last day of study participation (i. e., when they the Everion R© and the
final interview was conducted; Figure 2.6). Note that in the following
analysis, only complete cases (i. e., baseline and final values present) are
considered. Figure 5.7 shows that the medians of almost all symptoms
(over the study cohort) have not changed over the study period, except
for tiredness, which worsened. However, the IQR is shifted towards
a positive difference, indicating a worsening of symptoms, including
depression, minimal and current pain, tiredness and general wellbeing.
It is worth looking at the baseline itself, as presented in Figure 5.8.
Upon discharge from hosptial, a general lack of appetite was the symp-
tom with the largest IQR, together with poor wellbeing and tiredness,
followed by pain and fear. However, most patients were at a level of 5
or lower for most symptoms and were, therefore, stable.
5.4.2 Quality of life
The EORTC QLQ-C30 global quality of life (QL2) score is considered
as an early indicator of changes in quality of life. Physicians consider
decreases of the score of ≥ 10 % as relevant drops in quality of life. As
illustrated in Figure 2.6, patients had to fill out the questionnaire before
being discharged from hospital, referred to as ’baseline’ (BL),and were
then assessed in a weekly interview. Table 5.6 provides an overview
of the relevant drops in the study cohort. For 4 patients out of 29 (ex-
cluding patient 61 and 424 for aforementioned reasons), the baseline
QLQ-C30 values are missing. In this case, the first QLQ-C30 question-
naire from the weekly interviews is taken as a reference in order to
calculate relevant drops in quality of life.
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Table 5.6: Overview of patients with relevant drops in the global QoL
score (QL2). patid: patient id; no. interviews: number of interviews;
no. QL2 drops: number of relevant drops in score QL2; BL: baseline
value available
patid no. interviews no. QL2 drops BL
23 13 3 no
55 12 0 yes
69 8 0 yes
128 13 0 yes
142 10 3 yes
162 1 0 yes
165 14 1 yes
168 13 1 yes
183 12 1 yes
187 9 1 yes
192 10 7 no
193 11 1 yes
194 5 0 yes
216 7 6 yes
246 11 0 yes
271 11 0 yes
277 12 0 yes
319 10 1 yes
324 3 1 yes
340 9 2 yes
351 1 0 yes
355 9 0 no
359 11 1 yes
377 9 0 yes
405 10 4 yes
423 3 0 no
429 12 0 yes
430 7 0 yes
438 10 0 yes
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Figure 5.9 shows in detail the development of the QL2 score for
all patients. The red horizontal line indicates the baseline value if not
missing. The figure shows multiple patterns for the course of QL2:
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Figure 5.7: Box plot for the change of ESAS symptoms from baseline
(BL) to final over 23 patients. The x-axis denotes the symptoms, the
y-axis denotes the difference final − BL negative differences mean
improvement, positive differences mean worsening of symptoms. The
zero-line denotes no change in a symptom. The outliers are named
using the patients’ IDs.
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Figure 5.8: Box plot for the baseline scores of ESAS symptoms for 28
patients. Outliers are named with patient id.
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constant or improving Patients 55, 69, 128, 193, 194* 246, 271, 277,
355, 377, 429, 430 and 438 did not experience a relevant drop.
Instead, they were stable or recovering.
relevant drop and improving Patients 142, 168, 183, 319 and 340 ex-
perienced a relevant drop during the first month (405 in week 6)
and could recover to the baseline level or improve more.
improving, relevant drop, improving Patients 23, 165, 187, 359, 405
were stable or improving for the first weeks of the study before
experiencing a relevant drop from which they recovered.
relevant drop with little improving Patient 192’s health was mostly
worsening throughout her study participation with an improve-
ment during the last month. The original baseline value and the
first weeks are missing, because after her initial beginning, she
had to take a break from the study due to her delayed discharge
to home.
relevant drop with decreasing trend Patient 216* experienced a rele-
vant drop from the beginning and did not recover (downward
trend).
To summarise, the QL2 score dropped in the first month of study
participation rather than in later months. Most patients recovered and
were, by the end of the study, close to the baseline value or even
improved. Both, patient 194 and patient 216, passed away. Their reports
show different trends: Patient 194 reported an improved quality of
life, whereas patient 216 experienced a constant reduction in quality
of life. These different courses of the QL2 score belong to two patients
who passed away after experiencing different courses of their diseases.
Patient 194 had an acute emergency due to an epileptic seizure, which
happened without forewarning. Patient 216 experienced a continuous
worsening of his health.
5.4.3 Pain and distress
Figure 5.10 shows box plots for the answers to the digital question-
naires concerning pain and distress. These answers were recorded by
the smartphone app throughout the whole study period. 22 out of 30
patients had an increase of at least 2 points compared to the baseline
value at some point in time (relevant increase). The baseline value is
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defined as the first value. However, the small inter quartile ranges of
only up to 1 point for 22 patients (pain), 18 patients (distress) resp.,
and up to 2 points for 28 patients (both scales), illustrate the low vari-
ance in the digital self-reports and a strong stability of the subjective
perception of pain and distress over the whole study period.
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Figure 5.10: Variability of patients’ self-reports of (a) Distress and (b)
Pain. 22 out of 30 patients had a relevant increase (i.e., at least one
answer > 2 points compared to the BL value).
Table 5.7 shows that over study period, the median for both scales
did not move from the BL values for roughly half of the patients. The
first line of the table shows that for many patients (Pain: 8, Distress:
14), these symptoms improved compared to the baseline. Only for a
minority of the patients (Pain: 6, Distress: 4), the median over the study
period increased compared to the baseline values.
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Table 5.7: Number of patients that had an increased, decreased or
stable median (Pain, Distress) compared to the baseline.
Trend Pain Distress
median < BL 8 14
median == BL 16 12
median > BL 6 4
5.5 Analysis of emergency visits
In addition to evaluating the feasibility of the activity monitoring of
ambulatory patients in palliative care, the explanatory power of the
collected sensor data was investigated in the context of emergency
visits (EVs) to the hospital.
5.5.1 Overview
First, redundant features were identified and eliminated. The reduced
feature set was explored in order to discover features that showed
differences between the group of patients who experienced a non-
elective hospital visit (PEV) and the group without such an experience
(PnoEV).
The general idea comprises the following: For each patient, use
data from the beginning of their study participation as the baseline
behaviour or values (BL) (e.g., take the data from the first week spent
at home after discharge and compare the course of the patient’s data
to that original baseline).
As listed in Table 5.8, 11 patients experienced a non-elective hos-
pital visit during their study participation. In total, two of them (55,
340) were (non-electively) re-hospitalised while staying at a rehabilita-
tion unit and are, therefore, excluded from the analysis of this section.
Patient 351 experienced re-hospitalisation in the first week after dis-
charge, so not enough baseline data could be collected. Therefore, he
is excluded from the analysis below, too.
Two patients experienced two and four resp., non-elective hospital
admissions. Since after the discharge from hospital, a patient’s situation
might have changed drastically, a new baseline value would be needed.
Since the amount of data between consecutive emergency visits is not
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Table 5.8: Reasons for recorded non-elective visits in hospital dur-
ing study participation. sdn: number of study participation day; *:
included in data analysis
patid sdn stationary reason for emergency visit
55 11 yes new placement of jejunal tube after acci-
dental pull
162* 12 no bronchitis (coughing and thoracic pain)
162 29 no swelling and pain under right clavicle (DD
port infection, DD metastasis)
162 41 yes strong nausea and general weakness (as-
thenia)
162 84 yes dyspnea, pain and general weakness (as-
thenia)
183* 79 no low SpO2 of 80 %, abort of planned treat-
ment; clarification in emergency unit did
not reveal any changes
194* 38 yes seizure
216* 51 yes no information; reported earlier about in-
creasing pain
246* 72 yes kidney stone
351 7 yes nausea and vomiting, stomach pain
351 22 yes diarrhoea, nausea and vomiting, stomach
pain
340 8 yes progressive hemisyndrom left side as con-
sequence of growing cerebral oedema
405* 37 yes pneumonia (dyspnea and coughing)
423* 75 yes pyelonephritis
430* 48 yes general weakness (asthenia)
sufficient to create new baseline values, only the first emergency visit
of each patient is included in the analysis.
From the multi-variate time series of features, as described in Chap-
ter 3.4, the change of features between baseline (BL) measurements,
i. e., the measurements during the first week, and measurements close
to emergency events (EV) was extracted. Figure 5.11 illustrates which
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measurements were included in the following analysis.
1 6 12
Dismission 
Emergency
Event
weeks
Final
BL EV
BL
1 6 12
Dismission 
weeks
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Figure 5.11: Considered periods for t-test: (a) shows the case of a pa-
tient with emergency visit, (b) shows the case of a patient without
emergency visits. BL: the first week as baseline; EV: the event week
comprising all data 7 days before the day of the emergency visits in
situation (a) and all data of the last 7 days of the study participation in
situation (b)
For all features f i, i ∈ {1, ..,m} (m is the number of features) the
baseline value f iBL and the event value f
i
EV are calculated by taking the
median of all available measurement values (already aggregated to
hourly or daily values) and ignoring the missing values. The change
C( f i) of feature i is then calculated as the ratio between BL and EV:
C( f i) =
f iEV
f iBL
(5.1)
The calculations according to Equation (5.1) leads to a data set of
one value per patient and feature, i. e., a n ×m-matrix, where n = 30 is
the number of patients and m = 121 is the number of features as listed
in Table 3.14 and Table 3.15.
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5.5.2 Feature reduction
After removing features with zero variance (i. e., constant over pa-
tients), m = 115 features remained. With a pairwise correlation anal-
ysis of feature pairs < fi, f j, 0 ≤ i, j ≤ 114, i < j ≤ 115 j (leading to
n−1∑
i=1
i = n(n−1)2 = 6555 correlations according to Gauss [145]), highly
correlated features (|r| > 0.99, p < 0.05) were identified. Feature f j
was removed only if fi was not already removed (added to the list
indexDeletedFeatures in algorithm 5.1. If fi already has been re-
moved, feature f j is kept, because the highly correlated counterpart is
already eliminated, and one of the two has to be kept. This principle is
illustrated in Figure 5.12.
fi fi+1 fi+2 fi+3 fi+4
fi
fi+1
fi+2
fi+3
fi+4
>
.99
>
.99
Delete fi+2
Keep fi+4
check cor(fi,fj)
Figure 5.12: Illustration of the algorithm to reduce the feature space,
based on correlation analysis: The correlation matrix is calculated. Due
to its symmetry, only the upper triangle is processed. Pairs with r >
.99, p < 0.05, are checked: fi+4 has to be kept, because fi+2 is already
marked to be deleted.
This dimensionality reduction yielded a set of 80 remaining features
and is considered a cleaning step rather than a feature selection step.
These remaining 80 features were inspected visually using a parallel
plot [147]. Figure 5.13 provides an example of a parallel plot for ten
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Algorithm 5.1: Correlation-based feature elimination.
input : set of m features
output: list of indexes to be removed from feature set
indexDeletedFeatures← [];
for i← 1 to m − 1 do
for j← i + 1 to m do
if abs(cor( fi, f j))> 0.9 ∧ p < 0.05 then
if i < indexDeletedFeatures then
remove f j;
indexDeletedFeatures.append(j)
return indexDeletedFeatures
features. Each line represents the feature ratiosC( f i) of one patient. The
colour denotes the group. It is clear that none of the displayed feature
ratios are able to separate the two groups by itself. However, the resting
heart rate (RHR) and the resting heart rate variability (RHRV) show
the best separation of the two groups. This is confirmed by the density
plot shown in Figure 5.14. For plotting the densities, the features were
scaled to the range 0 to 1, using the transformation
scaled(xi) =
xi −min(X)
max(X) −min(X)
for X = {xi|i = 1, . . . , 30}.
The plotting function geom_density of the R package ggplot plots
a density estimate based on the data samples using a Gaussian ker-
nel density estimator [148]. The overlapping areas show which value
ranges of a feature occur in both patient groups. These overlapping ar-
eas would lead to misclassifications if the two groups were separated
based on these features.
5.5.3 Test procedure for group comparisons
Following an exploratory approach, statistical tests are conducted to
compare the described change of features C( f i) in the group of patients
who have experienced at least one emergency visit during their study
participation (PEV) and in the group of patients that have not experi-
enced any emergency visit during their study participation (PnoEV).
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Figure 5.13: Parallel plot for ten features. The x-axis presents the
features, the y-axis (log-scale) contains the values of these features.
Each line represents one patient, coloured by the patients group
(PEV/PnoEV). The dashed line represents the value 1 indicating no
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Figure 5.14: Density plots for ten features (scaled range [0, 1]) per
patients group (PEV: 7 patients, PnoEV: 20 patients).
These group comparisons serve to discover promising features, not to
show statistical evidence [149]. In total, three patients were excluded
from the PEV group, because they experienced the emergency visit
during their rehabilitation period or too soon (7 days) after their dis-
charge.
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Test selection
Since the group sizes are small (nPEV = 8, nPnoEV = 20, the statistical
test has to be chosen carefully. The test selection depends on the data
distribution in both groups, as illustrated in Figure 5.15. In this work,
the randomisation test was performed with 1000 permutations.
normal 
distribution 
?
visual inspection of 
normality & variance
T F
T T FF Homoscedas
ticity ?
Homoscedas
ticity ?
t-test Welch’s t-test
Wilcoxon rank 
sum test
randomization 
test
Figure 5.15: Test structure for comparison of groups: for all feature
ratios, the distribution of each group is inspected in terms of normality
and homoscedasticity, and the relevant test is chosen.
T – TRUE, F – FALSE
Examination of data distribution
The data distribution of each feature is examined group-wise using
box plots and quantile-quantile plots (q-q plots). The latter plots the
quantiles of the data versus the quantiles of a theoretical normal dis-
tribution. If the plotted points lie on or close to the plotted diagonal
line, the examined data is normally distributed. In addition to evalu-
ating the symmetry of the data distribution in each group, the box plot
also investigates wether the variances are sufficiently similar in both
groups.
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Interpretation of test results
As part of the feature discovery method, nominal significances are
reported for the features that are below the threshold of p < .05 [149].
For the Wilcoxon rank-sum test, the effect size r is calculated by
r =
z
√
N
where z is the z-score and N is the total sample size (i. e., the sum of
the two group sizes).
The randomisation test delivers the difference in means as test
statistics and a p-value.
5.5.4 Results: identified group differences
The comparison of groups delivered nominal p-values (p < .05)
for three features, namely RHR, RHRV and Vsteps (feature name:
acc.steps.speed in ref. Table 3.15: The daily mean of the speed of
steps is calculated, as measured by the smartphone in steps s−1). The
test results and further analysis of these three features are presented in
the following sections.
Resting heart rate (RHR)
Based on the data distribution of RHR in the groups PEV and PnoEV
(ref. section A.4.1), the Wilcoxon rank-sum test was applied, and a
randomisation test was performed as confirmation.
Conducting the Wilcoxon rank-sum test delivered the following
results: on average, patients of the PEV group had a larger ratio of the
RHR C( f RHR)(mdn = 1.01) than the PnoEV group (mdn = 0.79). This
difference was nominally significant W = 25, p = .021 with a medium-
sized effect r = .46. The randomisation test confirms the significance of
difference in means with p = 0.005.
The slope graph in Figure 5.16 shows that, for 4 out of 7 patients
with emergency visits, the median RHR was higher in the week before
the event than in the baseline week ( f RHREV > f
RHR
BL ), two patients had
a decreased median RHR and one patient saw no change. The RHR
of the PnoEV group changed for 13 out of 15 patients in the opposite
direction.
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Figure 5.16: a) Slope graph and b) slope summary for RHR. The lines
show the change of the resting heart rate for each patient from baseline
(BL) to the week before an event or at study end (EV). The table gives
a summary of the rising and falling slopes per patient group.
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Figure 5.17 shows a scatter plot where the baseline RHR values
are on the x-axis, and the final RHR values are on the y-axis. The ma-
jority of PEV cases lie above the black line, denoting a ratio of 1 (no
change); all samples of the PEV group lie below the black line, i. e.,
these patients experienced an increased RHR. Only three patients of
the PnoEV group (two of them very close to the border) experienced
an increase, too. According to the literature review, no studies have ex-
amined the relationship between resting heart rate and stage of cancer
development.
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Figure 5.17: Scatter plot showing the baseline RHR vs. final RHR.
The black line indicates no change.
According to experts, the normal range of RHR for adults is 60 bpm
to 100 bpm [150]. Common causes for tachycardia (higher heart rate) in-
clude hyperthyroidism, fever and heart insufficiency as well as drugs
and caffeine. As an example, patient 423 had diagnosed hyperthy-
roidism, with radio iodine therapy taking place in the month after
her study participation. Her RHR at the beginning of the study was
the highest of all patients and stayed almost constant over the study
period. Common causes for bradycardia (lower heart rate) include hy-
pothyroidism, opiates, barbiturates, tranquilisers, inflammations (like
meningitis and heart muscle inflammation) and increased physical fit-
ness. The RHR is influenced by many co-founders, e. g., excitement,
emotions, caffeine, stress, the weather and also depends on the time of
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the day. As a general health indicator, an increased RHR can signal a
worsened general health condition. The found difference in the groups
(increase in PEV vs. decrease in PnoEV) accords with the literature.
Resting heart rate variability (RHRV)
Based on the data distribution of RHRV in the groups PEV and PnoEV
(ref. section A.4.2), the Welch’s t-test was applied, and a randomisation
test was performed as confirmation.
The Welch’s t-test delivered the following results: on average, pa-
tients of the PEV group had a smaller ratio of the HRV metric (RMSSD)
C( f RMSSD) (mn=0.81) than the PnoEV group (mn=1.17). This difference
was nominally significant t(d f = 19.7) = 2.79, p = .011 with a large-
sized effect r = .53. When removing the outlier of the PEV group with
C( f RMSSD) = 1.09 (patient 430), the randomisation test confirms the
result with p = 0.43. A specificity of patient 430 is the following: af-
ter discharge from hospital, the patient lost weight (several kg) and
the elastic of the Everion R© was too wide for her arm. After consulting
the study team and after clarification from the manufacturer, she was
wearing the device on her calf. However, this new position can have
influenced the measurement.
The slope graph in Figure 5.18 shows that in fact, for 6 out of 7
patients with emergency visits, the median RHRV was lower in the
week before the event than in the baseline week ( f RHRVEV < f
RHRV
BL ), and
only one patient had an increased median. The RHRV of the PnoEV
group changed for 8 out of 16 patients in the opposite direction, with
five decreasing and three constant medians.
Figure 5.19 shows a scatter plot where the baseline RHRV values
are on the x-axis, and the final RHRV values are on the y-axis. Except
for one case, the black line denoting a ratio of 1 (no change), all samples
of the PEV group lie below the black line, i. e., these patients experi-
enced a decrease in the RHRV. However, a considerable number of
PnoEV patients also experienced a decrease and lie in similar ranges
for baseline and final value. A possible explanation for this is due to
the fact that the RHRV is influenced by many factors such as stress and
inflammation, which in many cases, does not lead to emergency visits.
The normal range of resting HRV (RMSSD) for healthy adults is
42 ms with a range of 19 ms to 75 ms [151]. However, a study fo-
cusing on cancer patients found a significantly reduced (RMSSD) of
24 ms ± 20 ms [152]. De Couck et al. argument that both causal direc-
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Figure 5.18: a) Slope graph and b) slope summary for RHRV. The lines
show the change of the resting HRV for each patient from baseline
(BL) to the week before an event or at study end (EV). The table gives
a summary of rising and falling slopes per patient group.
tions are plausible. The progress of tumours and reduced activity of
the vagal nerve have three common causes: the presence of free radi-
cals, excessive inflammation and activity of the sympathicus, which is
increased by stress. However, one study did show that low HRV pre-
dicted an increased risk for all cause (especially cancer) mortality [153].
However, the study considered only men in the age of 40 to 60 years.
Dekker et al. conclude that a reduced HRV indicates a compromised
health [153].
Step speed (Vsteps)
Based on the data distribution of Vsteps in the groups PEV and PnoEV
(ref. section A.4.3), the Wilcoxon rank-sum test was applied, and a
randomisation test was performed as confirmation.
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Figure 5.19: Scatter plot showing the baseline RHRV vs final RHRV.
The black line indicates no change.
On average, patients of the PEV group had a larger ratio of Vsteps
(mdn=1.1) than the PnoEV group (mdn=0.99). This difference was
nominally significant W = 11, p = .003 with a large-sized effect r = .61.
The randomisation test confirmed the significance with p = 0.003.
The slope graph in Figure 5.20 shows that in fact, for 5 out of 6
patients with emergency visits, the median Vsteps was higher in the
week before the event than in the baseline week ( f VstepsEV > f
Vsteps
BL ) and
one patient had a change smaller than 0.1. The Vsteps of the PnoEV
group remained constant (i. e., changed less than 0.1) for 9 out of 17
patients; decreases and increases occurred just as often (4 times).
Figure 5.21 shows a scatter plot where the baseline Vsteps values
are on the x-axis, and the final Vsteps values are on the y-axis. Except
for one case, which lies on the black line, denoting a ratio of 1 (no
change), all samples of the PEV group lie above the black line, i. e.,
these patients experienced an increase in the Vsteps. However, a con-
siderable number of PnoEV patients also experienced an increase, and
they lie in similar ranges for baseline and final value. A possible reason
for this is due to the fact that the Vsteps of the study cohort was diverse
in terms of walking capabilities, ranging from a farmer taking care of
his cattle to patients depend on a walking aid or a wheelchair. These
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Figure 5.20: a) Slope graph and b) slope summary for Vsteps. The lines
show the change of the Vsteps for each patient, from baseline (BL)
to the week before an event or at study end (EV). The table gives a
summary of the rising and falling slopes per patient group.
limitations of walking capabilities were not always a consequence of
the cancer, but originated from reasons independent of the cancer.
Subjective self-reports
Analogous testing of differences in the daily (pain, distress) and weekly
self-reports (QL2 – global quality of life and health score of QLQ-C30)
showed no significant differences between the PEV and PnoEV groups,
as listed in Table 5.9. Physicians consider the following changes in the
analysed scales (pain, distress, QL2) as relevant:
QL2: a drop of at least 10 % of the baseline value (at discharge)
Pain: an increase of at least 2 points compared to the baseline value
(first value)
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Figure 5.21: Scatter plot showing the baseline Vsteps vs. final Vsteps.
The black line indicates no change.
Distress: an increase of at least 2 points compared to the baseline value
(first value)
For all tests, only data before an emergency event was considered.
Note that for the digital scales, the ratios cannot be calculated for many
patients due to reported values of 0 in the baseline.
5.5.5 Recommended sample size based on power analysis results
Table 5.10 summarises recommended sample sizes that were estimated
by a power analysis (details of the power analysis are given in sec-
tion A.5).
Assuming a similar re-hospitalisation rate (10 out of 30; i. e., 1/3), a
total sample size of n = 60 as minimum should be targeted in future
studies. Considering a similar rate of re-hospitalisations that actually
could be included in the analysis (7 out of 28; i. e., 1/4 ), a total sample
size of n = 21 × 4 = 84 is recommended.
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Table 5.10: Minimal sample sizes for the RHR and RHRV hypothesis
testing for each group in case of nominal p = .05 and adjusted p with
Bonferroni correction, as well as the actual sample size n of PEV.
feature nominal p adj. p (2) adj. p (2) n
RHR 10 14 15 7
RHRV 16 19 21 7
Vsteps 5 14 17 6
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5.6 Discussion
5.6.1 Summary of results
Feasibility
Thischapter presented results on data completeness, showing that both
devices can be used for monitoring patients in ambulatory palliative
care. The devices were accepted by all patients, and most patients had
no difficulties with the devices or with the usage of the activity mon-
itoring app. The combination of forgetfulness and lack of experience
with smartphones reduces data completeness.
Differences in groups
Hypothesis testing revealed the following results:
• The exploratory analysis revealed, that the vital sign parame-
ters resting heart rate and resting HRV (RMSSD) as well as step
speed change differently in the two groups PEV and PnoEV with
nominal p-values < 0.05 (not corrected for multiple testing).
• The analogous analysis of features extracted from patients’ self-
reports did not unveil any significant differences between PEV
and PnoEV.
• Sensor signals, especially the vital signs resting heart rate and
resting HRV as well as the walking speed outperformed patients’
self-reports.
Predictive power of extracted features
Based on anomaly detection, emergency visits could not be predicted
(details are given in section A.6). Possible reasons for this include the
following:
• The study cohort varies in terms of cancer type, and co-
morbidities and life circumstances (e. g., city vs countryside, ac-
tive in work life vs bound to wheel chair, etc.). Therefore, the
extracted features are not only influenced by the worsening of
the disease, but also by other uncontrollable factors.
• During the study, different types of emergencies were observed
that may need different window sizes.
126 Chapter 5: Monitoring cancer patients in palliative care
• An in-subject analysis of the feature changes (details are given in
section A.7) revealed that patients are diverse and that individual
prediction models should be trained based on a patient-specific
feature selection.
5.6.2 Limitations
Sample size
In order to achieve statistically valid results, a study with a larger
sample size has to be performed.
Observational study
Since this study was observational with an exploratory study design,
not all parameters necessary to control important co-founding vari-
ables such as medication were tracked systematically. Furthermore,
the exploratory data analysis does not allow the stating of p-values.
Used devices
The used sensor is still under development. During the study period,
improved firmware became available, which was not used in order
to prevent artificial shifts in measurements. However, considering the
strict ethical requirements of study devices and the devices available
on the market, the Everion R© is still the best available option. Besides
the firmware and software under development, the battery capacity of
the Everion R© limited data completeness. Runtime and, therefore, data
completeness can be increased (up to 30 hours of runtime according
to the manufacturer) by sacrificing the SpO2 measurement. Another
solution is to equip each patient with two sensors worn alternately.
In this study, only Android phones were used. For a more natural
setting, also iPhones should be included.
Sparse ground truth
The only reliable ground truth of the collected data was that patients
went to hospital for emergency reasons or were re-hospitalised (al-
though there is no guarantee that all such events were registered) and
provided subjective self-reports. However, it is not guaranteed that all
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emergency visits (e. g., in a different hospital than the university hos-
pital in Zürich) were reported by the patients, and the circumstances
of emergency visits were not recorded in detail. Developed classifiers
could benefit from being trained with separate datasets with richer
and more precise labelling.

6
Conclusion and
outlook
This chapter summarises the thesis with focus on achievements and limita-
tions, leading to the final conclusions. The chapter ends with giving an outlook
for future work.
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6.1 Summary and achievements
This thesis investigates the possibilities of activity monitoring of out-
patients in palliative care by means of wearable devices such as smart-
phones and an arm-band. The topic comprises of three questions:
• How should a monitoring system look like in order to reduce
non-elective re-admissions to hospital for outpatients in pallia-
tive care?
• Is activity monitoring accepted by patients that have to deal with
a severe disease and face their end of life?
• Which sensor modalities are useful in order to predict non-
elective re-admissions to hospital?
To answer these questions, a monitoring system was developed fol-
lowing a patient-centric design involving interviews with palliative
cancer patients. The monitoring system consists of an activity moni-
toring app running on Android smartphones and an arm-sensor. The
activity monitoring app was evaluated in a pre-study in patients suf-
fering from cancer-related fatigue. The Everion R© was chosen as the
arm-band since it provides multiple measurements such as heart rate,
heart rate variability and galvanic skin response. At the same time, it
enables full data access and privacy control by means of an Android
SDK. Finally, the whole system comprising both wearable devices was
evaluated in an observational study involving 31 palliative cancer pa-
tients. This thesis features technical and methodological achievements
as well as medical achievements and findings.
6.1.1 Technical and methodological achievements
• An activity monitoring app was developed under consideration
of requirements concerning usability (power consumption, ques-
tionnaire design) and data security (storage and transmission)
and robustness. 37 patients with an age of up to 85 years used
the app over several weeks with positive feedback such as “easy
to use”.
• Conducting the studies unveiled a set of best practises and rec-
ommendations for future studies. For example:
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– A regular (time interval depends on buffer size of devices)
check of the data transmitted by the wearable devices is
necessary to improve data completeness.
– Weekly calls for interviews were appreciated by most pa-
tients as an opportunity to talk.
– Device-related questionnaires should be formulated in a
patient-focused way that focuses on the patient (“How are
you dealing with the devices?” instead of “How good are
the devices?”).
– A recommended cohort size n for future studies to confirm
the results of the palliative care study described in this thesis
was estimated by a power analysis. A future study should
target a minimum cohort size of 84 patients.
– The diversity of the study cohort ranged from active pa-
tients still going to work (e. g., taking care of their farm) to
patients bound to a wheel-chair and resting mainly at home.
To control this diversity, a future study can increase the co-
hort size and systematically log possible confounders such
as daily life circumstances and changes of medications or re-
strict the inclusion criteria resulting in a more homogeneous
study cohort.
• A feature extraction pipeline for efficient storage of data and of
processing results was developed. This pipeline comprises sev-
eral pre-processing steps like re-sampling and timestamp cor-
rection, GPS clustering, HRV analysis and feature extraction on
sliding windows. Emotion analysis based on voice and Wi-Fi
clustering was investigated.
• The possibilities and limitations to apply unsupervised methods
on a real-world dataset with sparse labelling and restrictions to
preserve the privacy of patients, were explored:
– Clustering of GPS data results in extraction of places. Home
clusters can reliably be identified as the cluster that is oc-
curring most often in the dataset of a patient.
– Clustering of Wi-Fi results in extraction of Wi-Fi situations.
However, the lack of additional labels or information about
rooms at the patients’ homes increased fine-grained loca-
tion uncertainty, e. g., in associating the extracted clusters
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to rooms of a patient’s home. Additional information such
as the number of rooms at a patient’s home can be used as
input parameter for a clustering method (e. g., number of
clusters) in order to facilitate the clustering and to increase
the interpretability of Wi-Fi clustering result.
– For emotion analysis of recorded phone calls, a classifier was
trained on an artificial dataset labelled with seven classes
of emotions. The classifier performance is comparable to
results reported in literature. However, the application on
the recorded phone calls faced two challenges: the recorded
audio may contain the voice of other speakers in the fore-
ground (e. g., the phone call partner) and background (e. g.,
television). Methods for speaker diarization and identifi-
cation of the relevant speaker as well as filtering of back-
ground noise have to be developed on a labelled dataset
that does not underly restrictions concerning privacy. Liter-
ature second-guesses that a classifier for emotions trained
on an artificial dataset will work with the same classifica-
tion accuracy. The lack of emotion labels does not allow to
evaluate the classification results on the real-world phone
calls.
– The analysis of vital signs worked well without additional
labelling. Additional information such as a patient’s hyper-
thyroidism was supported by the measured vital signs.
6.1.2 Medical achievements and findings
• For the first time, cancer patients in ambulatory palliative care
were observed over a period of 12 weeks by means of a weekly
assessment of QoL and a daily assessment of pain and distress.
In addition, a comprehensive dataset including physical activity
and social activity as well as vital signs was collected.
• Data analysis involving machine learning and statistics were ap-
plied to the data sets collected during the CRF study and the PC
study, unveiling new knowledge:
– Analysis of retention showed that activity monitoring with
smartphones and the Everion R© is accepted and feasible in
these patient groups.
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– The subjectively perceived CRF varies with multiple pat-
terns throughout the day.
– The self-reported daily pain and distress in palliative pa-
tients showed less variance than the weekly reported global
quality of life. Furthermore, a comparison of self-reports
between the groups PEV and PnoEV did not reveal any
significant differences.
– Palliative patients with emergency visits differed most sig-
nificantly from those without emergency visits in these pa-
rameters: resting heart rate and resting heart rate variability
as well as the speed of steps measured by the smartphone.
– The sensor data showed more differences between the two
groups than the self-reports.
6.2 Limitations
The studies conducted in this thesis followed an exploratory approach
with the goal to gain knowledge about feasibility and to identify fea-
tures of behavioural change related to emergency visits and quality of
life. The exploratory approach contains to the following limitations:
• Considering the number of diverse sensor modalities and fea-
tures analysed, the cohort sizes n of the studies are too small
(n ≤ 30) for parametric statistics and multiple testing.
• The diversity of the patient groups also hinders the aim to find
distinct and discriminative features. In a future study, inclusion
criteria should be more restrictive or more patient related data
should be logged systematically. This additional, patient related
data could be used by a predictive model or classifier to control
for such other parameters like changing treatments.
The observational study design allowed to gain first experiences
with activity monitoring of palliative outpatients. However, the obser-
vational design leads to the following limitations:
• When designing the study, it was unknown how many tasks
would the palliative patients tolerate. In order to not excessively
burden the patients, labelling tasks for the patients were limited
to the digital questionnaires once per day and to the weekly
interviews. As a consequence, labelling in the data set is sparse.
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• Since the palliative care study was designed as a feasibility study,
patients treatment and course of disease were not recorded sys-
tematically. As a consequence, changes in sensor data, e. g., re-
duced or elevated vital signs, can be due to a changed treatment
plan.
The used arm-sensor is still under development. The early devel-
opment state leads to the following limitations:
• The BLE connection was not reliable. This lead to additional
interaction with the patients resulting in a possible influence of
study results.
6.3 Conclusions
Based on this thesis, the following conclusions can be drawn:
• Remote monitoring as realised in this thesis is feasible and ac-
cepted in the examined patient groups.
• Predictive models have to be personalised because of the diver-
sity of the patients.
• Sensor-based activity monitoring outperformed patients’ subjec-
tive self-reports in this study cohort.
• Parameters with significant change before a non-elective visit to
the hospital were: resting heart rate, resting heart rate variability
and speed of steps.
6.4 Outlook
To advance research in this field, a larger study should be conducted.
The preparation need some additional development.
Activity recognition
More information can be extracted by using the Google API for An-
droid and Apple’s iOS ARKit or by developing a classifier on a labelled
dataset. However, when selecting or creating a dataset, one has to take
into account that the phone can be worn in any arbitrary position on
the body.
6.4. Outlook 135
Design of an Intervention
Following the recommendations of section A.8.2, a future study can
add an intervention in the form of a notification or call through a pro-
fessional care provider based on the identified feature candidates. The
design of the intervention should be explored by following a patient-
centric approach involving interviews. These interviews should in-
vestigate what kind of intervention patients would appreciate and
when it would be effective. The interviewees should be recruited from
non-elective re-admissions and non-elective ambulatory hospital vis-
its. The interviews should shed light on the course of events that led
to the emergency event. Through conversation with a patient, the in-
terviewer should try to identify the points in time where it would be
useful to intervene.
Continuous observation
During a future study, the data has to be observed and analysed con-
tinuously in order to start an intervention based on criteria that remain
to be defined. Therefore, a processing tool chain has to be developed
that processes automatically the incoming data on a daily basis and
delivers reports to the study staff. For the design of the reports, physi-
cians and other care givers could be interviewed in order to gather
ideas about optical form and content.
Voice analysis
Voice analysis could help to estimate a patient’s emotional status. There
is the need for further development in a natural setting with labelled
data to solve the issue of speaker diarization and use a natural emotion
dataset such as Wizard of Oz for building a classifier. There are also
pre-trained classifiers available [154]. However, none of them is trained
on a natural dataset. Furthermore, to reduce the amount of transferred
data, emotion recognition could be implemented on the smartphone.
More details on the topic of voice analysis is given in section A.3.1.

A
Appendix
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A.1 Performance scales
A.1.1 ECOG Performance Status
The Eastern Cooperative Oncology Group (ECOG) defined a perfor-
mance status that evaluates the capabilities of a patient from 0 (fully
active, without any restrictions compared to the pre-disease status) to
5 (death).
A.1.2 Karnofsky performance status scale
The Karnofsky performance status scale is another commonly used
status scale and can be mapped to the ECOG as shown in Table A.1.
Table A.1: Mapping between ECOG and Karnofsky.
ECOG Karnofsky
0 90 - 100
1 70 - 80
2 50 - 60
3 30 - 40
4 10 - 20
5 -
A.2 Used paper-based questionnaires
A.2.1 ESAS
The Edmonton Symptom Assessment Scale ia a validated question-
naire to assess crucial symptoms in palliative care patients [155]. It
consists of nine VAS assessing the following symptoms as perceived
by the patient during the last 24 hours:
• current pain
• maximal pain
• minimal pain
• tiredness
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• nausea
• depression
• anxiety
• drowsiness
• lack of appetite
• wellbeing
• other
For all scales, 0 means that symptom not existent (or best wellbe-
ing), 10 means that a symptom is very present.
ENGLISH 
 
 
EORTC QLQ-C30 (version 3)  
 
We are interested in some things about you and your health. Please answer all of the questions yourself by circling the 
number that best applies to you. There are no "right" or "wrong" answers. The information that you provide will 
remain strictly confidential. 
 
Please fill in your initials:  
Your birthdate (Day, Month, Year):  
Today's date (Day, Month, Year):  31  
__________________________________________________________________________________________ 
  Not at A Quite Very 
  All Little a Bit Much 
1. Do you have any trouble doing strenuous activities,  
 like carrying a heavy shopping bag or a suitcase? 1 2 3 4 
 
2. Do you have any trouble taking a long walk? 1 2 3 4 
 
3. Do you have any trouble taking a short walk outside of the house? 1 2 3 4 
 
4. Do you need to stay in bed or a chair during the day? 1 2 3 4  
 
5. Do you need help with eating, dressing, washing  
 yourself or using the toilet? 1 2 3 4 
 
 
During the past week:  Not at A Quite Very 
  All Little a Bit Much 
 
6. Were you limited in doing either your work or other daily activities? 1 2 3 4 
 
7. Were you limited in pursuing your hobbies or other 
 leisure time activities? 1 2 3 4 
 
8. Were you short of breath? 1 2 3 4 
 
9. Have you had pain? 1 2 3 4 
 
10. Did you need to rest? 1 2 3 4 
 
11. Have you had trouble sleeping? 1 2 3 4 
 
12. Have you felt weak? 1 2 3 4 
 
13. Have you lacked appetite? 1 2 3 4 
 
14. Have you felt nauseated? 1 2 3 4 
 
15. Have you vomited? 1 2 3 4 
 
16. Have you been constipated? 1 2 3 4 
 
 Please go on to the next page 
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A.2.2 EORTC QLQ-C30
The hereafter shown specimen of the QLQ-C30 [156] is protected by copy-
right and authorization for any use of a measure of the EORTC group has to
be requested by directly contacting the QoL-Department1 prior to usage.
1http://groups.eortc.be/qol/
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During the past week:  Not at A Quite Very 
  All Little a Bit Much 
 
17. Have you had diarrhea? 1 2 3 4 
 
18. Were you tired? 1 2 3 4 
 
19. Did pain interfere with your daily activities? 1 2 3 4 
 
20. Have you had difficulty in concentrating on things, 
 like reading a newspaper or watching television? 1 2 3 4 
 
21. Did you feel tense? 1 2 3 4 
 
22. Did you worry? 1 2 3 4 
 
23. Did you feel irritable? 1 2 3 4 
 
24. Did you feel depressed? 1 2 3 4 
 
25. Have you had difficulty remembering things? 1 2 3 4 
 
26. Has your physical condition or medical treatment 
 interfered with your family life? 1 2 3 4 
 
27. Has your physical condition or medical treatment 
 interfered with your social activities? 1 2 3 4 
 
28. Has your physical condition or medical treatment 
 caused you financial difficulties? 1 2 3 4 
 
 
For the following questions please circle the number between 1 and 7 that  
best applies to you 
 
29. How would you rate your overall health during the past week? 
 
  1 2 3 4 5 6 7 
 
 Very poor      Excellent 
 
 
30. How would you rate your overall quality of life during the past week? 
 
  1 2 3 4 5 6 7 
 
 Very poor      Excellent 
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Fragebogen 
zu Ihren Erfahrungen mit elektronischen Geräten 
 
Name, Vorname:___________________________Geburtsdatum:____________________ 
1.  Besitzen Sie eines oder mehrere der folgenden Geräte und wenn ja, wie lange schon 
benutzen Sie es?  
 Mobiltelefon seit _________ Jahren/ Monaten (Zutreffendes bitte unterstreichen) 
 Smartphone seit _________ Jahren/ Monaten 
 Tablet-Computer seit __________Jahren/Monaten  
 Laptop/Computer seit __________ Jahren/Monaten  
 Tracking-Armband oder Pulsuhr (z.B. Polar) seit __________ Jahren/Monaten  
 Blutdruckmessgerät seit __________ Jahren/Monaten  
 Blutzuckermessgerät seit __________ Jahren/Monaten  
 ______________________ seit __________ Jahren/Monaten 
 Besitze kein elektronisches Gerät 
2. Hatten Sie schon Umgang mit einem Schlafmessgerät?  
 Nein  Ja, und zwar  ___________________________________ 
3. Wenn Sie keines der Geräte besitzen, wären Sie dennoch an der Benutzung eines 
solchen Gerätes interessiert? 
 Nein, sicher nicht  Vielleicht/Kommt drauf an  Ja, interessiert mich 
4. Mögen Sie uns einen Grund für Ihre Antwort nennen? 
 ________________________________________________________________________
________________________________________________________________________ 
 ________________________________________________________________________ 
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A.2.3 Previous experiences with electronic devices
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Questionnaire 
on your experience with electronic devices 
 
Last name, first name:___________________________  Birthdate:____________________ 
 
1. Do you have one or several of the following devices and if yes, for how long have you 
been using it? 
 Mobile phone for _________ years / months (please underline what applies) 
 Smartphone for _________ years / months  
 Tablet computer for __________ years / months  
 Laptop / Computer for __________ years / months  
 Activity-tracking bracelet or watch (e.g. Polar) for __________ years / months 
 Blood pressure meter for __________ years / months 
 Blood sugar meter for __________ years / months 
 ______________________ for __________ years / months 
 I don't have any electronic device 
 
2.  Have you ever used a sleep monitoring device?  
 No  Yes, namely ___________________________________ 
 
3. If you don't have any of the abovementioned devices, would you still be interested in 
using one of such devices? 
 No, definitely not  Maybe / it depends  Yes, I'm interested 
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A.2.4 Previous experiences with electronic devices (englisch)
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Bewertungsfragebogen 
Wie geht es Ihnen mit den Geräten? 
 
1 Gab es in dieser Woche Probleme im Umgang mit den Geräten und wenn ja, welche? 
 Mit dem Aufladen Smartphone 
 Mit der Bedienung des Smartphones 
 Mit dem Aufladen des Trackingarmbands 
 Mit der Bedienung des Trackingarmbands 
 Mit der Anwendung der Apps 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
 
2a In den vergangenen 7 Tagen: An wie vielen Tagen haben Sie das Armband getragen? 
 1  2  3 4 5 6 7 
 
2b In den vergangenen 7 Tagen: In wie vielen Nächten haben Sie das Armband 
getragen? 
 1  2  3 4 5 6 7 
 
2b Was waren Gründe dafür, das Armband nicht zu tragen (tags oder nachts)? 
______________________________________________________________________ 
______________________________________________________________________ 
 
2c In den vergangenen 7 Tagen: An wie vielen Tagen haben sie das Smartphone 
immer bei sich gehabt?  
 1  2  3 4 5 6 7 
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A.2.5 How are you doing with the devices
Studie zur elektronischen Aktivitätsmessung 
Wöchentlicher Bewertungsfragebogen 
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2d Was waren Gründe dafür, dass Sie das Smartphone nicht bei sich trugen? 
______________________________________________________________________ 
_____________________________________________________________________ 
 
3a Die Bedienung der Apps (Schmerzskala und Distressthermometer)  
 fällt mir leicht  braucht etwas Gewöhnung  ist mühsam 
 
3c Was finden Sie an der Bedienung der Apps mühsam, was gefällt Ihnen nicht? 
______________________________________________________________________ 
______________________________________________________________________ 
 
4 Gibt es noch etwas, dass Sie uns in Bezug auf den Gebrauch der Geräte mitteilen 
möchten? 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
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Assessment questionnaire 
How are you doing with the devices? 
 
 1  In this week, did you have any troubles handling the devices and if yes, 
which? 
 Charging the phone 
 Operating on the phone 
 Charging the tracking bracelet 
 Operating on the tracking bracelet 
 Using applications on the phone 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
 
2a In the past 7 days: On how many days did you wear the bracelet? 
 1  2  3 4 5 6 7 
 
2b In the past 7 days: In how many nights did you wear the bracelet? 
 1  2  3 4 5 6 7 
 
2c Which were the reasons for not wearing the bracelet (in the daytime or at 
night)? 
______________________________________________________________________ 
______________________________________________________________________ 
 
2d In the past 7 days: On how many days did you always take the phone with 
you? 
 1  2  3 4 5 6 7 
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A.2.6 How are you doing with the devices (english)
Study on electronic activity tracking  
Weekly questionnaire 
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2d  Which were the reasons for not carrying the phone with you? 
______________________________________________________________________ 
______________________________________________________________________ 
 
3a  Operating in the applications (pain scale and distress thermometer) 
 is easy for me   requires some adaption   is difficult 
 
3b  What do you find difficult about using the applications, what do you dislike? 
______________________________________________________________________ 
______________________________________________________________________ 
 
4  Is there anything else you would like to tell us regarding the handling of the 
devices? 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
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A.2.7 NCCN Distress Thermometer
The NCCN published guidelines and a questionnaire to assess pa-
tients’ distress and problems [157]. The NCCN Distress Thermometer
cannot be included in this thesis due to copyright. The German ver-
sion as used in the palliative care study was validated by Mehnert et al.
[158].
A.2.8 FACIT-F
In this work, fatigue is assessed using the FACIT-F fatigue scale (ver-
sion 4) (Functional Assessment of Chronic Illness Therapy) [159]. It is
a validated instrument to measure fatigue in cancer patients as well as
patients suffering from other chronic diseases.
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Abschlussbefragung 
 
 
 
1. Wie ist jetzt nach Abschluss der Studie Ihr Gesamteindruck? Was ist gut gelaufen, was 
war schwierig? 
 
 
 
 
 
 
2.  Wie sind sie mit den Geräten zu Recht gekommen? 
 
 
 
 
 
3.  Wie regelmässig haben Sie sie getragen? 
 
 
 
 
 
4.  Wenn Sie sie nicht getragen haben, woran lag das jeweils? 
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A.2.9 Final interview
Studie zur elektronischen Aktivitätsmessung 
Patienteninformation und Einwilligungserklärung 
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5.  Gab es etwas, dass Sie als besonders lästig/unangenehm empfunden haben? 
 
 
 
 
 
6.  Gab es etwas, dass Ihnen gut gefallen hat? 
 
 
 
 
 
7.  Gab es Reaktionen aus Ihrer Umwelt/ von anderen Menschen und wenn ja, welche? 
 
 
 
 
 
8.  Gibt es Empfehlungen, die Sie uns als Forschungsteam geben, wenn sie jetzt daran 
denken, dass die Geräte regelmässig bei Patienten eingesetzt werden sollen? 
 
 
 
 
 
9.  Was würden Sie anderen Patienten über Ihre Erfahrungen sagen? 
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Final Interview 
 
ID, Date 
 
1. Now, after finishing the study, what's your general impression? What went well, what was 
difficult? 
 
 
 
 
 
 
2.  How did you manage handling the devices? 
 
 
 
 
 
3. How regularly did you wear them? 
 
 
 
 
 
4.  If you didn't wear them, what was the reason for it? 
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A.2.10 Final interview (english)
Study on electronic activity tracking  
 Final Interview  
 
 
 
Final Interview Version 1.1                                                                     Page 2 of 2 
5.  Is there anything you found in particular annoying/uncomfortable? 
 
 
 
  
 
6.  Is there anything you liked? 
 
 
 
 
 
7.  Did you get any feedback from your surroundings / other people and if yes, which was it? 
 
 
 
 
 
8.  Would you give us any recommendations as a research team if you imagine the devices 
to be used regularly with patients? 
 
 
 
 
 
9.  What would you tell other patients about your experiences? 
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A.3 Details of pre-processing methods
A.3.1 Voice analysis
For voice analysis, the python library [107] was used, since it provides
methods for all required tasks.
Voice Preprocessing
Since the audio files are encrypted and the privacy of the patients has
to be protected, the following steps are performed in a chain:
• decryption
• trans-code to wav format and delete decrypted file
• audio analysis task
• delete wav file
Segmentation
Usually, during phone calls, the speakers alternate. After analysis of
different phones used in the study, it turned out that not all data can be
used while preserving the privacy of the patients: some phones record
only the user of the smartphone, some phones record also the other
speaker. This leads to two segmentation tasks.
Silence removal. Using a SVM on features (MFCC, Spectral, Har-
monic, Chroma, zero crossing rate, energy, entropy, etc., more details
in [107]) extracted from 50 ms windows with 50 % overlap, the periods
of silence can be identified and removed. It remains segments of speak-
ing. The number of segments is equivalent to the number of turns in
case of phones that record only the smartphone user and not the call
partner. Figure A.1 gives an example
Speaker Diarization. Figure A.2 shows a conversation where prob-
ably both speakers are recorded since there is almost no silence. Since
this pattern shows in every call of patients using a phone generation
more recent than the Samsung Galaxy S5 and in none of the patients
using the Samsung Galaxy S5, a test with two such phones confirms
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Figure A.1: Silence detection using a SVM with probability output. The
in yellow highlighted areas are the periods of a conversation with voice
recognised. It is also visible, that only the smartphone microphone is
recorded.
that only the Samsung Galaxy S5 model records only the smartphone
user.
Having both voices recorded leads to the problem of speaker di-
arization which is usually tackled by clustering [107]. However, none
of the methods found in literature provides sufficient performance in
order to use it in a completely unsupervised manner. Furthermore, af-
ter identification of different speakers, the patient has to be recognised
out of all other speakers. methods for speaker diarization and identifi-
cation have to be developed and evaluated on a labelled dataset before
applying them to a dataset where the privacy of study participants has
to be protected. In a future study, a voice sample of each patient could
be taken in order to facilitate the task of voice identification.
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Figure A.2: Recorded phone call without silence periods and both call
partners recorded: silence removal marked with yellow the periods
with recognised voice.
Cosine similarity
It was investigated if voice features that are commonly used for emo-
tion classification change over the time. For each patient, all calls are
compared with each other. for each phone call, a feature vector is cre-
ated by the following method: after silence removal, a phone call is seg-
mented by the detected periods of silence. For each segment, features
as described in [107] are extracted and aggregated using the statistics
mean, min, max, range, standard deviation, kurtosis and skewness.
This aggregation leads to a vector of 238 features per segment. These
feature vectors are further aggregated by using the mean, yielding in
one feature vector per phone call. A phone call is reprepresented as
feature vector in a 238-dimensional vector space. For comparison, the
cosine similarity is calculated pairwise (i. e., for each pair of two feature
vectors Fi,F j, i, j = 1, . . . ,m; m number of phone calls). The cosine simi-
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larity is defined for two feature vectors F = ( f1, . . . , fn),G = (g1, . . . , gn)
as
cos(F,G) =
FG
‖F‖‖e‖
=
∑n
i=1 figi√∑n
i=1 f 2i
√∑n
i=1 g2i
Figure A.3 shows that from the extracted audio features, it is distin-
guishable when the patient was dismissed from rehabilitation. Some
calls show different similarities to the adjacent calls. The example
shows that it is important to consider also the environment as well
as contextual information for interpretation.
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Figure A.3: Pairwise cosine distances between phone calls. A) Calls
made during rehabilitation are very similar. The patient used the smart-
phone loudspeaker and background noise is hearable during weekly
interview (television); B) this day is different from other calls during
rehabilitation, but similar to calls made at home; C) Calls at home are
more similar to each other than to rehabilitation calls – especially the
last 6 calls
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Emotion recognition
To classify emotions, a SVM was trained on the EMO dataset [99]
using the same features as extracted during silence removal, with a
performance as listed in Table A.2. The classifier performs best for
sadness, anger and disgust.
Table A.2: Precision, recall and F1-score for 7 emotions.
Class Precision Recall F1-Score Support
A (fear) 0.69 0.6 0.64 15
E (disgust) 0.77 0.83 0.8 12
F (happiness) 0.55 0.61 0.58 18
L (boredom) 0.83 0.65 0.73 23
N (neutral) 0.56 0.78 0.65 18
T (sadness) 1 0.92 0.96 13
W (anger) 0.94 0.89 0.91 35
average/total 0.78 0.76 0.77 134
The confusion matrix of Figure A.4 shows that boredom and fear
are mainly mixed with happiness. However, [108] show that features
can differ between natural and acted emotions.
Conclusion for voice features
To conclude this section, it can be stated that voice features in terms
of similarity or classified emotions can be used when taking precau-
tionary measures to ensure that the input data are clean, i. e., only
the patients’ voice is recorded and background noise like television
is filtered out. Since the dataset of the palliative care study cannot be
cleaned sufficiently with preserving the patients’ privacy, voice fea-
tures are not used in later analysis.
158 Appendix A: Appendix
Figure A.4: Confusion matrix for emotion classification.
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A.3.2 Everion R© preprocessing: resampling algorithm
Algorithm A.1 was used to correct the timestamps of the Everion R©
signals.
Algorithm A.1: Correction of timestamp anomalies.
input : dataframe of vital signs with counter and timestamps
output: input dataframe with corrected timestamps
df← data to resample (input);
tDiff← -1, Diff(df.timestamp) ;
tDiff [last]← -1;
negGaps← indices where tDiff < 0;
segments← tuples (df [negGaps [i]:negGaps [i+1]],negGaps
[i],negGaps [i+1]), i ∈ 0, ..., last-2;
for s ∈ segments do
tDiffSegment← Diff(s[0].timestamp);
artCnt [0]← 0;
for i← 1 to length(s[0]) − 1 do
if tDiffSegment [i] == 0 then
artCnt [i]← artCnt [i-1] + 1
else
artCnt [i]← artCnt [i-1] + tDiffSegment [i]
resampleFactor← s[0].timestamp[last]−s[0].timestamp[ f irst]max(artCnt)+1 ;
newTime← s[0].timestamp[0] + resampleFactor ∗ artCnt;
updateTime(df [s[1]:s[2]], newTime)
return df
A.4 Data distributions of feature ratios
A.4.1 Distribution of RHR
As Figure A.5 shows, the data deviates from a normal distribution,
especially in the PnoEV group. The box plot shows a right skewness
in both groups. The variances in the groups are not equal, but the
difference between the variances is small (0.006). The q-q plots in b) and
c) show the deviations from the normal distribution for both groups.
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Hence, a Wilcoxon rank-sum test is preferred to a Welch’s t-test. Since
the variances are not equal, also a randomisation test was conducted
to confirm the result of the Wilcoxon rank-sum test.
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(b) q-q plot for RHR (PnoEV)
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(c) q-q plot for RHR (PEV)
Figure A.5: Analysis of distribution of RHR in the groups PEV and
PnoEV reveals that a Wilcoxon rank-sum test is preferred to a Welch’s
t-test because of the right skewness of the data, especially visible in a)
and b).
A.4.2 Distribution of RHRV
Figure A.6, subfigure a), shows that a Wilcoxon rank-sum test is not
advised due to different variances in the two groups (0.2). The box
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plot shows a right skewness in the PnoEV group. The q-q plot of the
PnoEV group (subfigure b)) shows sufficiently normally distributed
data points, when considering three largest points as outlier. Subfigure
c) allows to assume that the data of the PEV group are sufficiently
normally distributed for a t-test when considering the smallest and the
largest points as outlier. Therefore, a Welch’s t-test was conducted and
the result confirmed with a randomisation test.
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(a) Boxplot of RHRV
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(b) q-q plot for RHRV (PnoEV)
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(c) q-q plot for RHRV (PEV)
Figure A.6: Analysis of distribution of RHRV in the groups PEV and
PnoEV shows different variances in the groups (a)) and sufficiently
normally distributed data (b), c)) to allow a Welch’s t-test.
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A.4.3 Distribution of Vsteps
As Figure A.7 shows, the data in both groups are not normally dis-
tributed. The box plot in subfigure a) shows a right skewness in both
groups. The variances in the groups are almost equal with a difference
of 0.001. The q-q plots in b) and c) imply that both tests, Welch’s t-test
or a a Wilcoxon rank-sum test, are possible. To contribute to the right
skewness, the Wilcoxon rank-sum test is preferred. A randomisation
test was conducted to confirm the result of the Wilcoxon rank-sum test.
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(a) Box plot of Vsteps
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(b) q-q plot for Vsteps (PnoEV)
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(c) q-q plot for Vsteps (PEV)
Figure A.7: Analysis of distribution of Vsteps in the groups PEV and
PnoEV
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A.5 Power analysis for group comparisons
A power analysis for the three features RHR, RHRV and Vsteps was
performed. The power of a test describes the test’s capability to confirm
a hypothesis.
A.5.1 Methods for power analysis
For the t-test and Wilcoxon rank-sum test, different methods have to be
used for a power analysis. The term power is illustrated by Table A.3.
A statistical test estimates the probability of a null hypothesis H0, given
the data sample. If the test results in p < .05 (the commonly chosen
threshold), the null hypothesis is unlikely with a probability of less
than 5 %. Hence, α denotes the tolerated error rate that we accept HA
while H0 is true.
Table A.3: Confusion matrix for statistical tests, given a null hypothesis
H0 and an alternative hypothesis HA: the power is given by 1 − β
truth
H0 HA
predicted
H0 1 − α β
HA α 1 − β
Power analysis for a t-test. The power analysis for t-tests is per-
formed using the R package pwr [160]. The pwr package provides an
implementation of the analysis methods formulated by Jacob Cohen in
[161]. As input, the method requires the effect size d (Cohen’s d, given
by Equation (A.1)), the requested significance level and power and the
test type.
d =
m1 −M2
√
s21+s
2
2
2
(A.1)
where Mi denotes the mean of group i and si denotes the standard devi-
ation of group i. Cohen’s d is specific for each tested feature. Table A.4
lists the constant parameters as used in the following analysis. The
method returns the required minimum sample size for both groups.
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Table A.4: Fixed parameters for an independent, two-sided t-test for
testing of 1, 2 or 3 hypothesis with Bonferroni-corrected significance
levels
Parameter Value (1) Value (2) Value (3)
sig. level 0.05 0.025 0.0167
power 0.8 0.8 0.8
type two.sample two.sample two.sample
alternative two.sided two.sided two.sided
Power analysis for a Wilcoxon rank-sum test. To estimate the sample
size when using the Wilcoxon rank-sum test, a simulation is performed.
In general, a power of 0.8 is targeted. To estimate the necessary sample
size, a Wilcoxon rank-sum test is applied on randomly generated data
of a specific sample size and tested if p is smaller the required signifi-
cance level. This is repeated 1000 times yielding in a success rate (i. e.,
power) for the specific group sample sizes. To estimate the required
sample sizes, this repeated simulation is performed on a grid of sample
sizes with n denoting the size of group PEV and m denoting the size
of group PnoEV. As input, the method requires the group means and
a group standard deviation to generate the random group data as well
as the required significance level.
A.5.2 Power analysis for RHR
Since a Wilcoxon rank-sum test was performed to test the feature RHR,
the power is estimated through simulation. The random data is gen-
erated as normal distributions with mean 1.01 for PEV and mean 0.89
for PnoEV and a common standard deviation of 0.11 (i. e., the mean of
the standard deviations of the two groups).
From the performed power analysis, a heat map is generated show-
ing the power for given samples sizes n, m. Figure A.8 shows the sim-
ulation results for different significance levels. For the PEV group a
minimal size of 10 is needed (given a minimal sample size of 22 of the
PnoEV group) – up to 15 (given a minimal sample size of 25 of the
PnoEV group) in case of multiple hypothesis testing.
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(c) Power for p < 0.0167
Figure A.8: Power analysis for RHR and a Wilcoxon rank-sum test on
simulated data with a standard deviation of sd = 0.11.
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A.5.3 Power analysis for RHRV
Since an independent, two-sided t-test was performed to test the fea-
ture RHRV, the power analysis using the R package pwrwas used with
Cohen’s d = 1.037. For the three different significance levels, a sample
size per group of 16 to 21 patients is required. Compared to the sample
size of 7 in the PEV group, the power analysis shows that the result
should be confirmed as by an independent study with a larger study
cohort.
A.5.4 Power analysis for Vsteps
Since a Wilcoxon rank-sum test was performed to test the feature
Vsteps, the power is estimated through simulation. The random data
is generated as normal distributions with mean 0.99 for PEV and mean
1.1 for PnoEV and a common standard deviation of 0.066 (i. e., the
mean of the standard deviations of the two groups).
From the performed power analysis, a heat map is generated show-
ing the power for given samples sizes n, m. Figure A.9 shows the sim-
ulation results for different significance levels. For the PEV group a
minimal size of 5 is needed (given a minimal sample size of 13 in the
PnoEV group) – up to 17 (given a minimal sample size of 22 in the
PnoEV group) in case of multiple hypothesis testing.
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(c) Power for p < 0.0167
Figure A.9: Power analysis for RHR and a Wilcoxon rank-sum test on
simulated data with a standard deviation of sd = 0.066.
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A.6 Prediction of emergency visits
In this section, the question is examined if emergency visits can be
predicted based on recorded sensor signals.
A.6.1 Dataset for prediction
Out of 30 patients, 10 visited the hospital as an emergency. Two oc-
curred during rehabilitation stay and therefore are excluded from the
dataset. Therefore, 28 patients remained for the analysis. For the ap-
proach of anomaly detection by means of a one-class SVM, the dataset
is divided in a training set that contains only samples without emer-
gency samples and a test dataset that contains both, samples with emer-
gency (EV) and samples without emergency (noEV). The labelling of
samples is illustrated in Figure A.10. The dataset is split in two different
manners:
General dataset includes noEV samples from all patients in the train-
ing dataset and noEV and EV samples from the 8 patients of the
PEV group in the test dataset. This leads to a general classifier.
Patient-specific dataset generates 28 pairs of train/test datasets, where
the first 2/3 of the days are used as training dataset and the last 1/3
of the data is used as test dataset.
A.6.2 Feature extraction for prediction
As described in section 3.4, 121 features were extracted. These features
are used for the following analysis. This feature extraction yielded in
hourly or daily sampled multi-variate time series per patient. Features
on a sliding window of 5 days were extracted as illustrated by Fig-
ure A.10 by calculating mean and variance on the features described in
section 3.4 leading to 279 features. The last sample of the dataset of a
patient is either a) the one that is followed by a day with an emergency
visit or b) followed by the last day of study participation.
All features are standardised to mean=0 and sd=1. Features were
then selected by recursive feature elimination resulting in a set of 11
features as listed in Table A.5.
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Figure A.10: Rolling windows with labelling for emergency prediction.
a) depicts the case of a patient who as experienced an emergency visit,
b) depicts the case of a patient who had no emergency visit
A.6.3 Classification method to predict emergency visits
Since the dataset is unbalanced with at most one EV sample per patient
at 8 EV samples vs. 1703 samples without emergency visit, a binary
classifier is inadequate for a patient specific classifier. Hence, anomaly
detection by means of a one-class SVM with rbf kernel was applied.
A.6.4 Emergency prediction result
For the general dataset, the prediction result is low with an accuracy
of 0.7. As shown by the confusion matrix in Table A.6, only 3 out of 8
emergency visits are detected, whereas 25 % of the noEV samples were
wrongly detected as emergency visits. The detected emergency visits
were of the patients 183, 194 and 351. Further metrics for both classes
170 Appendix A: Appendix
Table A.5: Best feature set for one-class SVM.
feature mean variance
RHR ! #
RRR ! !
RHRV ! !
BLPW.mean ! !
BLPW.sd ! !
BLPE.mean ! #
BLPE.sd # !
are listed in Table A.7 and show that the detection of emergency visits
using a general classifier is not feasible. Possible reasons are:
• The study cohort is varying too much for the sample size.
• The circumstances of each patient and reasons leading to an emer-
gency visit or re-hospitalisation are different. Therefore, each case
should be considered separately.
• The fixed window size of 5 days does not reflect the different
causes for re-hospitalisation (e. g., epileptic seizure vs. deteriora-
tion of symptoms)
• If not an acute emergency (e. g., epileptic seizure) is present, the
decision to go to the hospital or try to stay at home is personal.
One patient might feel that she/he has to go to see a doctor,
whereas another would decide to try to stay at home. Therefore,
in addition to the small amount of available labels, the labels also
include subjective judgement that is not captured by any feature
and therefore cannot be taught to a classifier.
For the patient specific datasets, none of the 8 emergency visits
could be predicted. Patient individual feature selection can probably
improve this. The behaviour of features in individual patients is given
in section A.7.
A.7 In-subject analysis of features
Using the change of features C( f i), the complete feature set is analysed
for each patient. Table A.8 gives the frequencies how often a feature
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Table A.6: Confusion Matrix
for EV prediction
Predicted Class
noEV EV
Tr
ue
C
la
ss noEV 39 13
EV 5 3
Table A.7: Performance met-
rics of EV predic-
tion
noEV EV
Accuracy 0.7
Precision 0.88 0.18
Recall 0.75 0.36
F1-score 0.81 0.27
has the highest ratio event to baseline. Table A.9 lists the frequencies
of how often a feature is the top feature having the biggest decrease
with respect to baseline. Interestingly, the increasing ratios differ more
between the two patient groups than the decreasing features. In pa-
tients without emergency visit, the features measuring physical activ-
ity indicate that single patients had their biggest change in becoming
physically more active, e. g., they walked more or faster, had a higher
variance in the activity signal and covered a larger distance outside
from home. This indicates that over the study period, they could re-
cover.
In contrast, similar features decreas from baseline to event period
in both patients groups. The set of features with biggest decreases is a
mix of all sensor modality categories such as call statistics, GPS based,
physical activity and vital signs.
Figure A.11 shows a summary of the last week before an emergency
visit. The lighter a day, the more features were changed to an outlier
range (i. e., 1.5×IQR (inter quartile range)) at least for one hourly value
of that day. As comparison, the baseline week (BL) itself is shown. It
is the first week at a patient’s home. The week before the event (EV)
shows more variation than the baseline week, especially of patients
187 and 423. Most patients show in the EV week more increases than
decreases except for patient 430. For patients 183 and 246, there are
more changes during the last three days before the event, whereas for
the other patients, there is not a specific day at which a period with
more changes starts.
For comparison, Figure A.12 represents in the same way the last
week of study participation for PnoEV patients. Except for patients 23,
324, the baseline week (BL) and last week (EV) look similar.
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Table A.8: Number of biggest increases in patients ordered by fre-
quencies in EV patients.
Feature name noEV EV total
acc.var 2 2 4
cntComingHome 0 1 1
cntLeavingHome 0 1 1
cor.p 0 1 1
firstLeavingHomeDay 1 1 2
gsr.max 0 1 1
gsr.sd 0 1 1
maxDistFromHomeDay 0 1 1
step.cnt 4 1 5
acc.varDay 1 0 1
act.var 1 0 1
cnt.spo2 2 0 2
cntWalkingDay 2 0 2
gsr.mean 1 0 1
gsr.min 1 0 1
movingDay 1 0 1
movingPercent 1 0 1
movingPercentDay 1 0 1
step.speed.var 1 0 1
sumDistOutside 2 0 2
walkingpercent 1 0 1
walkingpercentDay 1 0 1
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Table A.9: Number of biggest decreases in patients ordered by fre-
quencies in EV patients.
Feature name noEV EV total
maxDistFromHomeDay 2 2 4
acc.varDay 2 1 3
cntWalking 1 1 2
firstLeavingHomeDay 0 1 1
ipi.lf_mean 0 1 1
maxDistFromHome 6 1 7
onbodypercentDay 0 1 1
sum.total.out 0 1 1
walkingpercent 1 1 2
cnt.spo2 2 0 2
gsr.sd 4 0 4
moving 1 0 1
movingPercent 1 0 1
sumDistOutside 1 0 1
t.range.day 1 0 1
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Figure A.13 shows the baseline values vs the final values (also EV
values). Points below the line indicate a decrease from baseline to final.
For all patients except 128 (active mother of 2 children, working in part-
time and only 49 years old), 187 (a farmer working on his farm during
the whole study period) and 23 (whose last check was negative and also
one year after study participation cancer-free), most of the features de-
creased towards the final time. For the three aforementioned patients,
most features increased. In general, many feature ratios are close to
the black line, meaning that they were almost constant. Analysing the
distribution of the modality categories, there is no pattern visible that a
specific category is mostly increasing or decreasing. However, the scat-
ter plot illustrates why a general prediction of emergency visits does
not work: the amount of changes very individual without generally
valid patterns.
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A.8 Recommendations for future work
The following recommendations are based on best practices developed
for the conducted palliative care study.
A.8.1 Recommendations concerning the contact with patients
Weekly contact
Most patients appreciated the personal weekly contact. Interviewers
should take the time to listen to patients.
Showing personal interest
Also questionnaires with a technical focus should be formulated in a
personal way to show compassion, e. g.,
impersonal How is the device handling?
personal How are you with handling the devices?
In the study, personal formulations were used which was appreciated
by the patients.
A.8.2 Recommendations concerning the study design
Study design
A future study design should take into consideration a control group
with a healthy population. Measurements of the control group can give
estimations for normal ranges. In addition, differences in the behaviour
between patient group and control group are probably more distinct
than between patients or over the time in one patient.
Sample size
The power analysis has shown that larger sample sizes are needed. In
order to test three hypothesis as resulting from section 5.6.1, at least 84
patients would be needed to avoid an underpowered study (ref. power
analysis in section A.5).
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Inclusion criteria
Depending on the features that should be examined, inclusion cri-
teria should be more strict by adding exclusion criteria such as co-
morbidities like heart diseases or sitting in a wheel chair.
Experience based sampling using digital questionnaires
In the palliative care study, the self-reports collected through the digital
questionnaires on the smartphone showed little variation. Even days
with emergency visits did not necessarily affect the reported pain and
distress. For example, a patient might fill out the questionnaire once in
the morning, still feeling good, and later in the afternoon, his situation
changes leading to an ambulatory emergency visit. After already re-
covering from the situation during night and the next day, he already
feels better so that the reported symptoms are again on the previous
level. Hence, instead of reporting the symptoms once per day at a ran-
dom point of time, future studies should request two reports: one in
the morning and one in the evening.
Systematic log
A log file with categorised entries (medical, organisational, technical)
was kept to store information about unusual events, important infor-
mations from the patient concerning the devices, their health condition,
absences, etc. It is also useful to explain implausible looking data, e. g.,
Everion R© step count is underestimated in patients with walking aids.
Furthermore, emergency visits should be logged in detail to allow to
consider the differing circumstances during data analysis.
In a future study, additional information about the patients should
be recorded systematically. Helpful for data analysis are
• medication of patients
• hospitalisation reasons and relevant unplanned visits of physi-
cians, including a diary over the course of events that led to the
emergency visit gained through a qualitative interview
• circumstances of daily living such as family, work, etc.
• information on co-morbidities, e. g., limited vision, physical lim-
itations like the need of walking aids
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A.8.3 Organisational recommendations
Documents and information exchange between organisations
Especially hospitals follow very strict policies concerning IT infras-
tructure. Encrypted e-mails are a practicable communication solution
preserving patients’ privacy. However, for collaborative editing of doc-
uments, e. g., the aforementioned log file, a solution, e. g., shared drive,
has to be established in collaboration with the IT departments of the
involved organisations.
Network provider
Depending on the local provider landscape and study protocol (e. g.,
provided SIM cards), much time consuming effort can be reduced by
using contracts instead of pre-paid cards. In addition, if patients keep
their SIM cards and change the smartphone, time for adaption of SIM
card size and support for data transfer to the new phone has to be
planned in advance in order to guarantee on time study start.
Mobile hotspots
In case of using Wi-Fi for data transmission, mobile hotspots should
be in stock. Some patients even did not know if they have Wi-Fi or not.
This can be clarified during a home visit.
Stock of devices
A stock of devices for 3 patients (depending on the lead time for all
material) should be always ready, since the period of announcement is
varying and can be short-term (e. g., discharge next morning).
Human resources
The expenditure of time should not be underestimated. The prepara-
tion of the study including the study design, system implementation
and application for ethical approval needed more than one year of one
person working full time on the project. For conducting the study, three
persons were in charge for screening and recruitment of patients, one
person (50 %) was responsible for the technical organisation, briefing
of patients and final interviews, one person (50 %) was responsible for
the weekly interviews and data input in the database.
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A.9 Tools for data processing
For data processsing, the following software packages were used:
• Python
– Python 3.5.1
– Pandas 0.21.0
– Numpy 1.11.3
– scikit-learn 0.19.1
– feather [148]
• R
– R 3.5.0 x64 [162]
– tidyverse [163]
– dbscan [136]
– ggplot2 [148]
– stargazer [164]
– pwr [160]
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